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Abstract
A rare disease is defined by the Rare Diseases Act of 2002 as a disease that currently affects
fewer than 200,000 patients in the USA. A pediatric population is one where the subjects are of
age 18 or less. These two crucial yet underserved types of populations come with their own lim-
itations in clinical trials. The paucity of potential trial enrollees and sensitivity of these patients,
combined with a lack of sufficient natural history and experience, presents several economical,
logistical and ethical challenges when designing clinical trials. An increasingly well accepted
approach to address these challenges has been data extrapolation; that is, the leveraging of
available data from adults or older age groups to draw conclusions for the pediatric population.
Bayesian hierarchical modeling facilitates the combining (or “borrowing”) of information across
disparate sources, such as adult and pediatric data.
In this thesis we begin by developing, illustrating, and providing suggestions for Bayesian
statistical methods that could be used to design improved clinical trials for pediatric and rare
disease populations that efficiently use all available information. A variety of relevant Bayesian
approaches are described, several of which are illustrated through two case studies: extrapolating
adult binary efficacy data to expand the labeling for the drug Remicade R© to include pediatric
ulcerative colitis, and a simulated continuous longitudinal dataset patterned after an evaluation
of the drug cinacalcet in treating pediatric secondary hyperparathyroidism (HPT).
The thesis then turns to methods useful in the study of X-linked adrenoleukodystrophy (X-
ALD), a rare neurodegenerative disease for which Lorenzos Oil (LO) is one of the few available
treatments. We offer a hierarchical Bayesian statistical approach to understanding the phar-
macokinetics (PK) and pharmacodynamics (PD) of LO, linking its dose to the plasma erucic
acid concentrations by PK modeling, and then linking this concentration to a biomarker (C26,
a very long-chain fatty acid) by PD modeling. Next, we design a Bayesian Phase IIa study to
estimate precisely what improvements in the biomarker can arise from various LO doses while
simultaneously modeling a binary toxicity endpoint. Our Bayesian adaptive algorithm emerges
as reasonably robust and efficient while still retaining good classical (frequentist) operating
characteristics. Future work in this area looks toward using the results of this trial to design a
Phase III study linking LO dose to actual improvements in health status, as measured by the
appearance of brain lesions observed via magnetic resonance imaging.
Finally, the thesis shows how to utilize the rich PK/PD data to inform the borrowing of
information from adults during pediatric drug development. Here we illustrate our approaches
in the context of evaluating safety and efficacy of cinacalcet for treating HPT in pediatric and
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adult patients. We use population PK/PD modeling of the cinacalcet data to quantitatively
assess the similarity between adults and children, and in turn use this information in various
hierarchical Bayesian rules for borrowing from adults, statistical properties of which can then
be evaluated. In particular, we simulate the bias and mean square error performance of our
approaches in settings where borrowing is and is not warranted to inform guidelines for the
future use of our methods.
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Chapter 1
Introduction
1.1 Data Extrapolation in Rare and Pediatric Diseases
A rare disease is defined by the Orphan Drug Act of 1983 as a disease that currently affects
fewer than 200,000 patients in the USA. Disease rarity not only reduces the possible candidates
and cases available for study and research, but also limits patient natural history and experience
available. A pediatric disease is one that affects individuals aged 18 or less as define by section
529(a)(3) to the Federal Food, Drug, and Cosmetic Act (the FD&C Act). Studies involving
drugs targeted at pediatric or rare diseases require special attention, as they present several
economical, logistical and ethical challenges26,15,7.
In the United States, legislative actions have been taken to promote research in these fields,
such as the Best Pharmaceuticals for Children Act6, Pediatric Research Equity Act44, and the
Orphan Drug Act43. As the populations involved are often more sensitive as well as fewer in
number, we wish to minimize the risk involved while maximizing the little information we have.
It would be very helpful if we could borrow information from all available data sources, both
to help substantiate our results from the current study and to attempt to reduce the needed
sample size. Borrowing historical data information has been well explored in regulatory science
for medical devices, with guidance documents available from FDA11,12. However, borrowing
information in the case of drugs is a not as straightforward, as the pharmacokinetics (PK) and
the pharmacodynamics (PD) of the drug may be very different in, say, adults and children, and
hence the response from children may be different from that of the adults51. Also, drugs are
often approved for an adult population and prescribed off-label to children with only minimal
understanding of the vagaries of pediatric response. Later, the sponsors often wish to conduct
new studies to test the drug specifically in the pediatric population. In such studies it is unethical
to subject more children to experimentation than absolutely required, motivating use of the
1
2adult data from other clinical trials or any other historical dataset to strengthen the analysis and
reduce the pediatric sample size. Many extrapolation techniques10 have been used to streamline
pediatric drug development and help speed approvals of drugs for pediatric labeling.
Bayesian statistical methods easily facilitate adaptive dose-finding and other early-phase
studies, permit formal borrowing of strength from other information sources including expert
opinion and previous data, and yield probabilistic inference regarding model quantities of interest.
In this thesis we will look at Bayesian methods in several phases of clinical trials specifically
related to rare and pediatric diseases, with emphasis on data extrapolation techniques to facilitate
more efficient and ethical clinical trials.
We begin Chapter 2 with a look at hierarchical Bayesian models to evaluate and analyze
Phase II-III rare and pediatric data. This is a particularly crucial area for borrowing of information
from historical or adult datasets, since there is a need for Type I error control in these later, often
regulated phases. We will look at various methods to borrow information, including power priors
and commensurate priors. We will test methods using binary data from clinical trials pertaining
to the drug Remicade (infliximab), which was under review by FDA as a treatment for pediatric
unlcerative colitis. Next we formulate piecewise linear models for continuous longitudinal data
and show how data extrapolation can be carried out with such models using a Bayes-Markov
Chain Monte Carlo (MCMC) approach. We consider power and commensurate prior methods, as
well as more standard methods as summarized by Thompson and Pennello53. We illustrate the
methods to leverage data using a simulated dataset patterned after a real dataset we describe
below.
Next, in Chapter 3 we expand our attention to the pharmacokinetics and pharmacodynamics
(PK/PD) stage, and expand our hierarchical Bayesian modeling to drug PK/PD. Here we are
motivated by a data set from a study on the effect of Lorenzo’s Oil (LO) for patients with X-
linked adrenoleukodystrophy (X-ALD), a rare disease of primarily young boys. Using information
from our PK/PD modelling, we design a Phase IIa clinical trial for LO efficacy and toxicity that
fine-tunes the dose administration per patient’s personal response. In our design, we compare
the use of standard Emax and approximating linear PD models, the latter of which can offer
statistical computational benefits, especially when simulating trial operating characteristics.
Chapter 4 then introduces a novel method to utilize PK/PD data to inform the amount of
borrowing of information from previous adult data during the later clinical phases of pediatric
drug development. The basic idea here is that if the PK/PD properties of the drug are similar
in adults and children, this helps justify borrowing more liberally from the adult data in later
phases of the pediatric development program. Here again we tackle the case of longitudinal
continuous data, and develop models for both efficacy alone, and efficacy and safety jointly. We
3then use these models to analyze a dataset on pediatric secondary hyperparathyroidism (HPT),
where our power prior is calibrated using PK/PD data from related adult and child studies.
We then perform a simulation study to help shed light on the proper choice of calibration of
our power prior. We close this chapter with preliminary results for a piecewise linear version
of our longitudinal model, and some discussion of alternate methods for measuring adult-child
similarity in the PK/PD data.
Finally, Chapter 5 concludes and summarizes the work. In particular, Section 5.1 focuses on
direct extensions of the methods in Chapters 2-4, while Section 5.2 proposes a modified version
of Zellner’s g prior and describes its use in data borrowing from historical and adult datasets.
We also analyse simulated Gaussian data based on the Remicade example using hierarchical
Bayesian modeling, and again incorporating tools from borrowing methods such as power priors
and commensurate priors. We also propose to develop better methods for selecting g in this
setting.
1.2 Datasets Used in the Thesis
1.2.1 Remicade for Pediatric Ulcerative Colitis
In Section 2.2 we consider a beta-binomial model for binary response data illustrated with a
recent dataset on the drug Remicade R© (infliximab), a drug approved by the FDA to treat
Crohn’s disease, ulcerative colitis (UC), rheumatoid arthritis, and other conditions. We have
data from two adult UC clinical trials, called ACT 1 and ACT 2, as well as one pediatric UC
clinical trial called T72. Both ACT 1 and ACT 2 had patients who were administered infliximab
at a dose 5mg/kg. The pediatric trial T72 had only 60 pediatric patients who were administered
infliximab at 5mg/kg. This uneven sample size is often prevalent in such clinical trials, where
the drug has been tested in adults previously and should be treated with caution.
Our endpoint of interest here is based on the observed Mayo score which is a commonly
used activity index in placebo-controlled clinical trials for UC. The score is further elaborated in
Chapter 2. The binary nature of the dataset as well as the uneven sample size across the trials
present an interesting case study for the use of Bayesian data extrapolation methods in clinical
trials. The dataset is further elaborated in the chapter along with its analysis.
1.2.2 Lorenzo’s Oil for X-ALD
In Chapter 3, we analyze a PK/PD data from young boys suffering from X-ALD. We are
interested in the effect of Lorenzo’s Oil (LO) administration on the change in C26:0 plasma
concentration in these boys, while adjusting for various covariates specific to individuals and
4observations, such as the dose of LO administered, the weight of the patient, etc. LO is a 4:1
mixture of oleic and erucic acid, and administration of LO is known to increase levels of erucic
acid in the plasma.
The analyzed dataset contains data from 116 subjects screened for this study at the John
Hopkins Research Hospital from 2000 to 2014 under an expanded access trial (ClinicalTrials.gov,
NCT02233257). Diagnosis of X-ALD was confirmed by plasma SVLFCA assay. These asymp-
tomatic X-ALD children were followed until they developed any brain MRI abnormality. The
patients returned to the clinic every few weeks for their blood samples to be collected, which
resulted in one observation per visit. The lack of detailed observation per dose cycle of the
patients presents a limitation to the usual PK/PD analysis. For the PK/PD analysis we are in-
terested in the patients’ erucic acid concentration, C26:0 level obtained from the blood samples
and also each patient’s weight in kg. Since the patients display elevated levels of C26:0, the
average improvement in C26 level for each patient is the primary quantity of interest in our PD
analysis as well as the Phase IIa trial. We look at further details and analysis in Chapter 3.
1.2.3 Cinacalcet for Pediatric Secondary HPT
We have two sets of data from clinical trials for cinacalcet, namely a dataset for a PK/PD
analysis, and a Phase III clinical trial dataset.
Data for PK/PD Analysis
The dataset for PK/PD analysis consists of data from 7 clinical studies, 3 of which are adult
studies (Amgen studies 20000172, 20000187 and 980126), and the remaining 4 pediatric studies
(Amgen studies 20070208, 20110100, 20030227 and 20090005). The adult studies include a
Phase III randomized controlled study with 403 patients (20000172), a Phase II study with
60 patients (980126), and a Phase I study with 22 patients (20000187). The pediatric studies
include 2 studies with older pediatric patients aged 6-18 years (20070208, a Phase 3 randomized
controlled study with 43 patients, and 20030227, a Phase I study with 12 patients), and 2 studies
with younger pediatric patients aged 28 days to less than 6 years (20110100, a Phase 2 study
with 11 subjects, and 20090005, a Phase 1 study with 12 patients). Due to the sequential nature
of the PK/PD analysis explained later in the section, we have the posterior estimates of the
PK analysis necessary for the PD analysis. We also have extensive patient specific observations
necessary for the PD analysis, including the iPTH and cCa observations which constitute the
crucial feedback loop in the model.
5Data for Phase III Efficacy and Toxicity Analysis
The clinical efficacy and toxicity response data are further analyzed in Section 4.3. These
data came from three adult Phase III clinical studies (20000172, 20000183 and 20000188) and
one pediatric Phase III study (20070208). The three adult studies have similar study designs
and were randomized, placebo-controlled clinical trials with subjects aged at least 18 years
with secondary HPT receiving dialysis. Total sample size in these adult studies is N=1136.
The pediatric data were collected from the 30-week, double-blind, placebo-controlled phase of
pediatric study 20070208. The study enrolled N=43 subjects aged 6 to 18 years with secondary
HPT receiving dialysis. During the course of the studies, a cinacalcet dose was given daily, and
labs including iPTH and cCa were measured every two weeks. The percent change in the level
of iPTH indicates the efficacy of the drug, whereas the drop in the level cCa below a threshold
value is an indicator of toxicity in the patient.
Chapter 2
Hierarchical Bayesian Models for
Clinical Data Extrapolation
2.1 Background
As mentioned in Chapter 1, statistical borrowing of strength for auxiliary data can offer a way
forward in rare and pediatric drug and device approvals. In this chapter, we lay out such models
for both continuous and binary data, and illustrate their application to two rare and pediatric
disease settings.
2.1.1 Classical Statistical Approaches to Data Extrapolation
The traditional approach to analyzing a trial for pediatric diseases, where the drug has already
been approved for adults, is to carry out a study on children and analyze it without any infor-
mation borrowed from adult data. Depending on the type of dataset at hand, as well as the
background clinical information, a wide variety of models can be fit to explain the dose-response
relationship. These could be simple linear models, random or mixed effects survival models,
piecewise linear regression models, or logit models for binary response datasets. Classical ap-
proaches include fitting simple frequentist random or mixed effects models to just the pediatric
trial data, which is now routinely done using software packages such as R and SAS. An example
for such a model is given in (2.1), where we regress the mean response µij from the i
th child’s jth
observation on the time from baseline, denoted here by Timeij , the dose of the drug, denoted
by Doseij , and introduce a subject-specific random intercept γi:
µij = γi + β1Timeij + β2Doseij . (2.1)
6
7For a continuous observation Yij , a sensible likelihood is
Yij
ind∼ N(µij , σ2Y ), i = 1, ...., nc, j = 1, ......mi, (2.2)
for some σ2Y > 0 where nC is the number of children. However, this approach ignores the
information in the adult dataset.
An alternate but still naive approach would be to pool all adult and child observations into
one big dataset and then fit a model. This uncritical pooling of the pediatric and adult datasets
may be inappropriate in many settings. A slight improvement to this procedure is to fit the
regression once to the adult data and again to the pediatric data, and then take an appropriate
weighted average of the pediatric and adult results. These weights could be based on the sample
sizes of the two datasets, or perhaps expert opinion about the drug and the disease. However,
the weight selection is crucial but difficult to justify in a traditional statistical framework.
A key aspect of such problems is the basis upon which extrapolation is deemed appropri-
ate. Several pieces in the literature have discussed this issue10, where a systematic review of
approaches for matching adult systemic exposures is often used as the basis for dose selection in
pediatric trials submitted to the FDA. The literature refers to two categories of extrapolation,
full and partial extrapolation. Full extrapolation is when adult data are used directly to establish
pediatric safety or efficacy. These extrapolations rely on data supporting the assumptions that
there are similar disease progressions, responses to intervention, and exposure-response rela-
tionships in the adult and pediatric populations. Pediatric development supported by pediatric
pharmacokinetic and safety data or pediatric safety data alone can be considered adequate. By
contrast, partial extrapolation is when adult data are statistically combined with pediatric data
to make such determinations. Partial extrapolation of efficacy is used when there is uncertainty
about at least one of the assumptions underlying complete extrapolation, as mentioned above.
In such cases, pediatric development could be based on a PK-PD study to confirm response in
the pediatric population, followed by a single, adequate, well-controlled pediatric trial to confirm
the efficacy seen in adults.
2.1.2 Current Bayesian Approaches
The approaches mentioned so far work well when we have a fairly rich pediatric dataset and also
understand the disease and drug mechanisms reasonably well. However when we are working with
pediatric or rare diseases, we wish to use every bit of information available to us. In such cases,
Bayesian methods can help strengthen our analysis through their ability to combine multiple
information sources. Current Bayesian approaches include fitting hierarchical models5,8,30 to
both the adult and pediatric data together, where the parameters connecting the two datasets
8are related at some deeper level of the hierarchy. As an illustration, let us assume we have three
datasets: two adult datasets D1 and D2, and a pediatric dataset D0. Let the numbers of patients
in each of these datasets be n1, n2, and n0, respectively, and let i = 1, ...n1, ...(n1 + n2), ..., n
denote the patient index, where n = n1 + n2 + n0 denotes the total number of patients. Then
assuming a simple linear fixed effects model like the one in (2.1), having likelihood (2.2), we
can construct the following hierarchical model:
µij = γa,i + βa,1Timeij + βa,2Doseij for i = 1, ..., (n1 + n2)
µij = γc,i + βc,1Timeij + βc,2Doseij for i = (n1 + n2) + 1, ..., n,
γa,i ∼ N(γ0a, σ2a), γc,i ∼ N(γ0c, σ2c ), γ0a, γ0c ind∼ N(γ0, σ2γ)
and βa,k, βc,k
ind∼ N(βk, σ2βk) for k = 1, 2. (2.3)
We may proceed to assign hyperpriors to γ0, β1, β2, and the variance parameters based on
prior information from other data, such as crude auxiliary estimates of these numbers if possible,
or using vague priors that let the data direct the values of these parameters. Such hierarchical
models are widely used and often yield sensible results. Such models can however be constructed
to incorporate much more prior information than shown above, leading the hierarchy to become
more complicated and possibly rely too much on the adult data. Viele58 and Hobbs et al.18
also stress that such “static borrowing” (where the amount of adult data incorporated is fixed
ahead of time) can lead to biased estimates when the two data sources do not agree. Also,
when we rely on vague hyperpriors, the model may be computationally improper and our MCMC
algorithm may fail to converge, thus rendering the Bayesian approach futile. Care should thus be
taken to incorporate all prior information and expert opinion regarding the problem at hand, as
well as to be reasonably parsimonious with parameters. Note also that all borrowing is implicit
through the exchangeability of the βa,k and βc,k. Thus this method is simple, but doesn’t allow
us to explicitly control the amount of borrowing between the datasets.
An alternative to fitting an exchangeable model for the datasets together is to take a two-
step approach, where we first fit a hierarchical model to the adult dataset, and then use its
posterior estimates as the priors in a second statistical model for the pediatric dataset. This
method is illustrated in a real-life setting in Subsection 2.3.1. We might also downweight the
adult information used by introducing various scaling parameters in the priors for the pediatric
model.
In the longitudinal continuous data setting, suppose we first fit the adult model to our
adult data and obtain posterior means and variances for γ0a, βa,1 and βa,2, which we denote
informally by γˆ0a, σˆ
2(γˆ0a), βˆa,1, σˆ
2(βˆa,1), βˆa,2, and σˆ
2(βˆa,2). Then in Step 2, we assume
γ0c ∼ N(γˆ0a, α0σˆ2(γˆ0a)), βc,1 ∼ N(βˆa,1, α1σˆ2(βˆa,1)), and similarly for βc,2 using α2 to scale
9the prior variance. The three hyperprior variance scaling parameters (α0, α1 and α2) help us
control the amount of borrowing from the adult data. In other words, we center our priors for
these parameters at the posterior estimates we have obtained for the adults, but downweight
this information by choosing α’s bigger than 1. When these values equal 1, we assume full
borrowing from the adult information.
A slightly more sophisticated and flexible method to facilitate data extrapolation while re-
taining control on the amount of borrowing is through the use of the power prior25. This
approach downweights the supplemental (adult) likelihood by raising its likelihood in the poste-
rior calculation to a power that is between 0 and 1. Assuming we wish to regress our response
variable on some independent variables and the parameter of interest is θ, the power prior based
on two adult datasets is
pi(θ,λ|D1, D2) ∝
[
2∏
k=1
L(θ|Dk)λk
]
pi(θ) , (2.4)
where λ = (λ1, λ2) and the initial prior pi(θ) is often vague. Note that λk controls how much
information will be borrowed from auxiliary (adult) dataset k to supplement the (fully-utilized)
child data; e.g., λk = 1 means full borrowing from source k, while λk = 0 implies no borrowing
from this source. Such control is important in cases where there is heterogeneity between the
supplemental and primary data, or when equal weighting of primary and all supplemental data
sources is inappropriate. In fact, for fixed power priors, there is a one-to-one relationship between
the power parameter and the effective sample size in the prior. The relationship is particularly
straightforward in the normal likelihood setting; see for example Morita et al.33,34 and Penello
and Thompson45.
Finally, the commensurate prior approach18,19,20 is an even more fully adaptive method
to account for the commensurability between the adult and pediatric datasets. It essentially
specifies a hierarchical model with posterior
p(θc, θa, η|D0, D1, D2) ∝ L(θc|D0)L(θa|D1, D2)pi(θc|θa, η)pi(θa)pi(η) . (2.5)
Hence the so-called commensurate prior for the child parameter vector θc, pi(θc|θa, η), is usually
centered around the corresponding parameter for the adult data (e.g., N(θc|θa, η−1)). The
amount of borrowing can be modified by tuning the precision η of the prior around θa. A larger
variance would imply we have less faith in the similarity of the pediatric and adult data, and
therefore allow the pediatric estimate to be farther from that of the adult. Hobbs et al.20 recom-
mend a “spike and slab” hyperprior for η, which helps crystallize the choice between borrowing
and not borrowing. Both this method and the power prior method are also demonstrated in our
Subsection 2.3.2 case study.
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ACT 1 (adult) ACT 2 (adult) T72 (pediatric)
Infliximab 5mg/kg Infliximab 5mg/kg Infliximab 5mg/kg
Endpoint n = 121 n = 121 n = 60
Clinical response 84 (69.4%) 78 (64.5%) 44 (73.3%)
Clinical remission 47 (38.8%) 41 (33.9%) 24 (40.0%)
Mucosal healing 75 (62.0%) 73 (60.3%) 41 (68.3%)
Table 2.1: Study-level endpoint data, Remicade UC studies in adults (ACT 1 and ACT 2) and
pediatrics (T72)
All Bayesian models described above can be fit using standard Bayesian software such as
OpenBUGS31, Stan (mc-stan.org), Proc MCMC in SAS, or in R using packages available in
CRAN (cran.r-project.org) or those that call BUGS or its variants from R, such as rjags.
2.2 Binary Response Model
As discussed in Section 1.2.1, we look at a beta-binomial model for binary response data on
the drug Remicade R© (infliximab). Its maker sought a meeting with a gastrointestinal (GI) FDA
advisory panel for the purpose of expanding the drug’s labeling to include pediatric ulcerative
colitis. As is common in such settings, extrapolation from adult data was not permitted for
dosing or safety assessment in children, but the panel did allow the sponsors to argue for
extrapolation of efficacy using two existing adult studies. Ultimately the panel did decide in
favor of full extrapolation, but no quantitative modeling was involved in this decision, only
clinical judgment.
The summary statistics of the data seen by the advisory panel have appeared in the literature23,24.
Recapitulating from Section 1.2.1, our data comprises of K = 2 UC trials in adults (called ACT
1 and ACT 2) and one UC trial in pediatrics (called T72). The efficacy endpoints in these trials
are based on the Mayo score derived from the subscores of its 4 components: stool frequency,
rectal bleeding, endoscopic findings, and physician’s global assessment. The Mayo score has
a minimum value of 0 and a maximum value of 12. The primary efficacy endpoint of clinical
response at week 8 is defined as a decrease in the Mayo score by at least 30% and 3 points,
with a decrease in the rectal bleeding subscore of at least 1 point or a rectal bleeding subscore
of 0 or 1. When this definition is met, the clinical response is 1; otherwise, it is 0. The sec-
ondary endpoints are presence or absence of clinical remission and mucosal healing at week 8.
Table 2.1 gives the summary statistics of the endpoints. In the remainder of this section, we
apply Bayesian binary methods to these data, obtaining quantitative summaries that might have
helped the panel make a better-informed decision.
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Two Step Prior Commensurate Prior Power Prior
r (ESS) E(θ3|D,D0) (CI) κα (ESS) E(θ3|D,D0) (CI) α0(ESS) E(θ3|D,D0) (CI)
0.01 (62.4) 0.729 (0.616,0.832) 1 (62.4) 0.730 (0.622,0.837) 0 (62) 0.725 (0.615, 0.835)
0.25 (121) 0.687 (0.607,0.761) 10 (84) 0.724 (0.620,0.828) 0.25 (123) 0.710 (0.631, 0.790)
0.5 (181) 0.667 (0.602,0.728) 50 (181) 0.705 (0.617,0.793) 0.5 (183) 0.705 (0.638, 0.770)
1 (302) 0.659 (0.606,0.711) 100 (302) 0.700 (0.622,0.778) 1 (304) 0.700 (0.648, 0.752)
Table 2.2: Results for the various Bayesian models fit to the study-level Remicade data.
2.2.1 Two-step Approach
Let Yjk denote the binary outcome on the primary endpoint for patient j in study k, and
Yk =
∑J
j=1 Yjk denote the summary statistic for the primary endpoint total in study k, k =
1, 2, 3. Thus, the adult data is D0 = (Y1, Y2) and the pediatric data is D = Y3. We assume
that Yk ∼ Binomial(nk, θ0), for k = 1, 2 and use a conjugate Beta(κaµa, κa(1 − µa)) prior
on θ0. We complete the model specification by assigning hyperpriors κa ∼ Uniform(2, 122)
and µa ∼ Beta(1, 1), where the upper bound for κa was chosen to be comparable to the
sample size of either of our adult datasets. The posterior distribution for a given κa and µa
is Beta(κaµa +
∑2
k=1 Yk, κa(1− µa) +
∑2
k=1(nk − Yk)). Note that the support of (κa, µa) is
(2, 122)× (0, 1).
In step 1, given only the adult data D0, denote the posterior means of κa and µa by
κˆa and µˆa, and use these in the prior for the pediatric dataset. Specifically, we assume θ3 ∼
Beta(rκˆaµˆa, rκˆa(1− µˆa)), where we use r ∈ (0, 1) to scale down the adult data effective sample
size (ESS), κˆa, as the pediatric population (n3=60) is much smaller than the combined adult
populations (n1 + n2 = 242). Note that r can be either assumed known or have a Beta(1, 1)
prior; in the latter case is determined from the data. Here, we assumed that r is known. In
step 2 of this two step approach, we update the Binomial(n3, θ3) likelihood for Y3 to obtain
a Beta(rκˆαµˆα + Y3, rκˆa(1− µˆa) + n3 − Y3) posterior for θ3. Note that the empirical pediatric
success rate is slightly higher than that of the adults, and hence when we borrow more strength
from the adult data, the θ3 estimates should decrease, and the corresponding 95% credible
intervals should get narrower.
The results for various choices of r (corresponding to ESS values ranging from 62.4 up to
the full combined sample size of 302) are given in the first two columns of Table 2.2. Notice
that as we increase the r, the θ3 point estimate decreases (from 0.729 down to 0.659) and the
corresponding 95% credible interval widths also decrease (from 0.216 down to 0.105), both as
expected. In this model, the choice of r is somewhat subjective, but values greater than 0.5
result in 60/181 = 33% or less of θ3 posterior’s strength coming from the pediatric data, which
may be insufficient for regulatory approval.
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2.2.2 Combined Approaches
In this section we first fit a commensurate prior model. In particular, we choose a Beta(1, 1)
distribution as our initial prior on θ0 and take θ3|θ0 ∼ Beta(κθ0, κ(1−θ0)) as our commensurate
prior, with κ ∼ Gamma(κα, 1) and κα assigned a fixed value. The commensurate prior approach
then specifies a hierarchical model with posterior
p(θ3, θ0, η|D,D0) ∝ L(θ3|D)L(θ0|D0)pi(θ3|θ0, η)pi(θ0)pi(η) . (2.6)
Thus the joint posterior in this case arises as
pi(θ3, θ0,κ|D,D0) ∝
θY33 (1− θ3)n3−Y3θY1+Y20 (1− θ0)n1+n2−Y1−Y2θκθ0−13 (1− θ3)κ(1−θ0)−1κκα−1e−κ. (2.7)
While this does not lead to a closed form for the marginal posterior p(θ3|D,D0), sampling from
the distribution is routine via the BUGS language. The results for varying values of κα are given
in Table 2.2; the ESS values shown for this method are computed as functions of our posterior
estimates. As in the case with the two-step approach, increases in κα are again associated with
clear decreases in the θ3 point estimates and interval widths, though the shrinkage back to the
adult values is less dramatic here.
Finally, we also apply the power prior method to our data. Here we may begin by assuming
that θ0 = θ3 = θ, instead of putting a homogeneity constraint on the θks. We then obtain
the posterior p(θ|D,D0) as proportional to L(θ|D)L(θ|D0)pi(θ). The power prior approach25
downweights the supplemental (adult) likelihood by raising it to a power α0 that is between 0
and 1. The power prior then arises as
pi(θ,α0|D0) ∝
[
2∏
k=1
f(Yk|θ)α0,k
]
pi(θ)pi(α0) . (2.8)
Note that α0,k controls how much information will be borrowed from the auxiliary (adult) data
to supplement the fully-utilized child data; e.g., α0,k = 1 means full borrowing from source
k, while α0,k = 0 implies no borrowing. Such control is important in cases where there is
heterogeneity between the supplemental and primary data, or when equal weighting of primary
and supplemental samples is inappropriate. In fact, if the power priors are fixed, there is a
one-to-one relationship between the power parameter of the power prior and the variance of the
prior; the relationship is particularly straightforward in the normal likelihood setting.
We fix the powers α0,k = α0 for k = 1, 2, thus specifying a fixed and equal amount of
borrowing from both adult studies. Notationally, we have Yk ∼ Binomial(nk, θ3) and θ3 ∼
Beta(κµ, κ(1 − µ)), where we choose minimally informative values κ = 2 and µ = 0.5. Then
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θ3|D,D0 ∼ Beta(κ˜µ˜, κ˜(1 − µ˜)), where κ˜ = κ + n3 +
∑2
k=1 nkα0 and µ˜ = κ˜
−1(κµ + YK+1 +∑K
k=1 Ykα0,k). The results for four representative values of α0 (and corresponding ESS values)
are given in the last column of Table 2.2. The effect of increasing ESS is again apparent, with
the now-familiar trends in the posterior means and interval widths being somewhat intermediary
to those arising from the previous two methods.
2.3 Continuous Longitudinal Response Models
Throughout this section our interest is driven by the cinacalcet data described in Section 1.2.3.
Mimicking this dataset, we simulate datasets from both adult and pediatric clinical studies of
Cinacalcet in the context of a linear mixed effects Bayesian hierarchical model to study the drug’s
effect on iPTH. Cinacalcet has been shown to lower the parathyroid hormone (PTH) released
by the parathyroid glands, which in turn reduces the level of calcium and phosphorous released
from the bones. The iPTH (intact PTH) test level is of key interest, and is routinely monitored
for people with chronic kidney disease; lowering it by some clinically significant percentage is
a goal of many efficacy trials in this area. The number of patients in the pediatric dataset is
assumed to be just nc = 40, whereas we suppose there are na = 800 patients in the adult
study, a level of imbalance not uncommon in practice. Let Xi,j be the percent change in the
iPTH level of patient i (i = 1, ..., nc, ..., (nc +na)) in the week of the patient’s j
th observation,
j = 1, ...,mi (where mi varies from 3 to 25). That is:
Xi,j =
iPTHi,j − baseline iPTHi
baseline iPTHi
× 100 . (2.9)
This percentage change will be our outcome variable in the linear model. Let ti,j denote the
week after baseline for the jth observation on the ith patient. Since here we assume we don’t
have precise dosing information for every patient, our model (2.1) for the children becomes
Xci,j ∼ Normal(µci,j , 1/τ ce ), i = 1, ..., nc
where µci,j = µ
c
1it
c
i,j + I(drug
c
i = 1)(µ
c
dt
c
i,j). (2.10)
Here µc1i are the subject-level random effects, assumed to independently follow a N(η
c
0, τ
c
η)
specification, and µcd is the fixed effect of the drug on each child’s slope. Note we do not include
intercepts in model (2.11) since Xij is defined to be 0 at baseline (tij = 0). Similarly for the
adults, we assume
Xai,j ∼ Normal(µai,j , 1/τae ), i = nc + 1, ..., nc + na
where µai,j = µ
a
1it
a
i,j + I(drug
a
i = 1)(µ
a
dt
a
i,j). (2.11)
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Now the µa1i are subject-level random effects, assumed to independently follow a N(η
a
0 , τ
a
η )
specification, whereas µad is the fixed effect of the drug on the slope of the fitted iPTH percent
change variable. Regarding hyperpriors, both ηc0 and η
a
0 are assigned flat hyperpriors, µ
c
d and µ
a
d
are assigned vague normal priors, and we place vague G(0.1, 0.1) hyperpriors on τ ce and τ
a
e .
2.3.1 Two-Step Approach
We first fit a two-step model along the lines of those described in Section 2.1.2. Specifically, in
Step 1 we fit the adult model to our adult data and obtain posterior means and variances for ηa0 ,
and µad, which we denote by ηˆ
a
0 , σˆ
2(ηˆa0), µˆ
a
d, and σˆ
2(µˆad). Then in Step 2, we use these posterior
estimates to guide our pediatric analysis. Specifically, we assume ηc0 ∼ N(ηˆa0 , α0σˆ2(ηˆa0)) and
similarly µcd ∼ N(µˆad, αdσˆ2(µˆad)). The next question is therefore what the values of α0 and αd
should be. They can be assigned based on expert knowledge, such as how similar clinicians
think the two populations are likely to be and thus how much borrowing can be justified. As
mentioned above, such static borrowing is straightforward but clearly somewhat subjective.
Alternatively, we can assign hyperpriors to the α’s, such as a vague gamma or “spike and slab”
distribution. However in some cases this may not be a good idea as it is often difficult to specify
this hyperprior, and no information in our data exists to inform this decision.
A quantity sometimes used to guide this decision is the effective historical sample size
(EHSS)19, which generalizes our notion of ESS in the beta-binomial case of Section 2.2. Various
definitions exist, but a straightforward one53 for a parameter of interest ξ is
EHSS(ξ) = nc
[
V ar(ξ|Xc)
V ar(ξ|Xc, Xa) − 1
]
, (2.12)
which is the percent improvement in ξ’s posterior precision (inverse variance) arising from using
the chosen fraction λ of the adult data, expressed on the same scale as the child sample size.
Note that other metrics (e.g.,
√
V ar−1) might have been chosen in (4.1), and that the answer
will vary with the choice of ξ.
In our case, we take the overall fitted slope in the drug group, ηc0 + µ
c
d, as the primary
parameter of interest ξ. Ideally the effective historical sample size should be no greater in
magnitude than the pediatric sample size, since even though we are trying to borrow strength
from the adult data, our analysis should be primarily driven by the pediatric data. However for
our simulated data we often see EHSS values approaching or even exceeding the actual adult
sample size of 800, since definition (4.1) is simple but may perform erratically in more complex
hierarchical models, especially when implemented via MCMC.
Tables 2.3–2.5 contain the results of the methods applied to our simulated data. We look at
the estimated posterior mean and standard deviation (sd), the 95% equal tail Bayesian credible
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ηc0 η
c
0+µ
c
d
BCI BCI BCI BCI
α mean sd lower upper EHSS mean sd lower upper EHSS
1 0.67 0.35 -0.04 1.35 1139.02 -3.12 0.53 -4.15 -2.08 703.1
7 1.13 0.86 -0.59 2.78 102.17 -2.60 1.24 -5.05 -0.19 96.94
15 1.54 1.14 -0.76 3.74 73.02 -2.24 1.59 -5.39 0.86 42.86
100 3.05 1.92 -0.76 6.72 0 -1.76 2.29 -6.31 2.69 0
Table 2.3: Posterior estimates for the model coefficients using a two-step approach for various
values of α.
interval (BCI), and the calculated EHSS corresponding to the placebo effect, ηc0, and the overall
slope in the treatment group, ηc0 +µ
c
d. The latter indicates whether the patients in the treatment
group showed improvement over time.
In Table 2.3 we fit our two-step model using three different values of α = α0 = αd to
show the effect of borrowing. The posterior estimates from Step 1 were ηˆa0 = 0.5659 and
µˆad = −3.805. Note that as α increases, the estimates for the children become more dissimilar
to those of the adults. Note also that for the vaguest prior (α=100), we obtain the child
data-only results (EHSS=0), which also have the largest estimated sd’s. It appears for around
α = 15, EHSS(ηc0 + µ
c
d) is fairly close to the actual size of the pediatric dataset (nc = 40).
It should also be noted that based on the upper limit of the BCI for ηc0 + µ
c
d, for example, the
significance of our findings for the primary parameter change with α. In our case the change
happens around α = 7; smaller values lead to statistically significant findings, whereas larger
values do not.
2.3.2 Combined Approaches
In this subsection we begin by fitting a commensurate prior model. We assume our model for the
adults is as defined previously. We also model the pediatric data similar to before, but modify
its prior to adaptively learn from the adult data based on their estimated similarity. Following
(2.6), we assign the prior for ηc0 as N(η
a
0 , 1/τc), and the prior for µ
c
d as N(µ
a
d, 1/τdc) to introduce
the commensurability. We then proceed to assign spike and slab hyperpriors on τc and τdc as
follows:
τc ∼
{
Normal(200, 0.01) with probability f ;
Uniform(0.1, 5) with probability 1− f,
and τdc ∼
{
Normal(200, 0.01) with probability f ;
Uniform(0.1, 5) with probability 1− f,
16
ηc0 η
c
0+µ
c
d
BCI BCI BCI BCI
p mean sd lower upper EHSS mean sd lower upper EHSS
1 0.58 0.15 0.29 0.87 7827.4 -3.23 0.15 -3.53 -2.94 9464.6
0.9 0.75 0.77 0.29 3.57 244.54 -3.02 0.93 -3.61 0.15 211.08
0.65 1.33 1.50 0.19 5.45 35.36 -2.47 1.66 -5.13 1.66 38.43
0.5 1.77 1.78 0.14 6.11 13.73 -2.18 1.91 -5.73 1.98 19.35
0 3.28 2.06 -0.72 7.38 0 -1.72 2.32 -6.36 2.83 0
Table 2.4: Posterior estimates for the model coefficients using the commensurate prior for various
values of p.
η0 η0+µd
BCI BCI BCI BCI
λ mean sd lower upper EHSS mean sd lower upper EHSS
0.1 0.78 0.16 0.46 1.09 8504.4 -3.01 0.16 -3.32 -2.71 10706.6
0.001 2.24 1.11 0.07 4.40 137.31 -2.57 1.12 -4.72 -0.33 169.99
0.00015 3.23 1.68 -0.09 6.52 37.22 -2.11 1.76 -5.52 1.48 44.43
0 4.11 2.34 -0.392 8.84 0 -1.46 2.56 -6.46 3.47 0
Table 2.5: Posterior estimates for the model coefficients using the power prior for various values
of λ.
where we assume a single spike probability f ∼ Bernoulli(p) for both τc and τdc. We can now
vary the amount of borrowing by varying the value of p. An increase in p would mean a higher
chance of the precision taking a value close to 200, our “spike”, and hence more borrowing from
the adult data. By contrast, small values of p encourage small τ values in the “slab”, which
discourages adult borrowing. Relatively little information on τc and τdc exist in the data, so the
spike and slab parameters must be tuned carefully.
Table 2.4 contains the results of this model for varying values of p. As can be seen, the
results show the expected trends regarding borrowing between the datasets. For p = 0, we
again get values consistent with no borrowing (EHSS=0). The EHSS(ηc0 + µ
c
d) indicates
a p of 0.65 delivers an EHSS approximately the size of the pediatric dataset. However the
EHSS does increase greatly for p > 0.9, becoming more than the available number of adult
patients (na = 800). As noted in the case of the two-step approach, the significance of our
findings changes with an increase in p, reemphasizing the caution with which the value of these
parameters should be chosen. For ηc0 + µ
c
d, the change seems to occur around p approximately
0.9; the BCI contains zero for smaller p, and does not contain zero for very large p.
Finally we fit a power prior model. Here we may begin by assuming that ηa0 = η
c
0 = η0 and
µad = µ
c
d = µd. We then obtain the posterior p(µd|Da, Dc) as proportional to L(µd|Dc)L(µd|Da)λpi(µd).
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For this method the EHSS was especially sensitive to the choice of λ. It appears that a very
small λ of 0.00015 is needed to yield an EHSS close to the size of the pediatric dataset. The
BCI for η0 + µd again shows that the significance of our findings change with a change of λ.
The upper boundary of the BCI for λ = 0.001 is close to zero, with this value roughly forming
the break between Bayesian significance and insignificance.
If we fit a model as in the first step of the two-step approach to the pediatric data alone, the
posterior estimate of ηc0 is 4.518 and η
c
0 +µ
c
d is –2.02. As can be seen, for all 3 methods in Tables
2.3–2.5 as we move down the columns, the amount of borrowing from the adult data decreases
and the obtained posterior estimates are now closer to those obtained by a hierarchical model
on the pediatric data alone. Since p in the case of commensurate priors and λ in case of power
priors vary from 0 to 1, it is easier to intuitively set their values in accordance with our prior
knowledge. EHSS performance is somewhat unstable in Table 2.5, suggesting the commensurate
approach may be preferable. If we wish to limit the EHSS to roughly the pediatric sample size
(nc = 40), we must conclude the drug does not lead to a significant improvement in iPTH
percent change under any of our three methods. However if we can tolerate a higher EHSS
(say, greater than 5nc), for example due to added clinical justification or relaxed restrictions on
borrowing, we can arrive at significant results and conclude that the drug shows improvement
in pediatric populations as well.
We also investigated individual mean levels for two individuals in our simulated dataset,
numbers 35 and 9. The 35th individual had iPTH observations larger than the other pediatric
patients, whereas the 9th patient was more or less randomly chosen and is not outlying. In both
cases, EHSS could not be reliably estimated due to Monte Carlo error and the inherent smallness
of these values. Thus EHSS does not seem to be a helpful tool in the case of individual random
effects.
2.4 Outlook
As demonstrated by our Section 2.2 and Section 2.3 examples, several Bayesian modeling tech-
niques exist to facilitate borrowing information between datasets for which we can control the
degree of borrowing. Caution should be exercised when using these methods, especially when
the datasets are very dissimilar and the adult or other historical dataset has the potential to
sway the answers overmuch. That being said, given sufficient familiarity with these methods and
corresponding software, they can be used in a wide variety of problems to strengthen analysis,
especially in studies of pediatric and rare disease where we have to work with smaller sample
sizes for ethical and logistical reasons. As noted above, with an increase in α, decrease in p or
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decrease in λ, the statistical significance (i.e., whether the BCI includes zero), reemphasizing
that the question of how to pick the degree of borrowing often remains hard to answer. The
amount of borrowing can be based on several factors, such as expert opinion, or similarity be-
tween the adult and pediatric datasets. Our methods provide a way to quantify the trade-off
between obtaining significant findings and fully justified adult data borrowing. However, more
experience is needed with the spike and slab and other hyperpriors that control the degree of
borrowing.
Chapter 3
Bayesian Models for PK/PD and
Phase IIa Studies in Rare Diseases
3.1 Motivating Example in Rare Disease
X-linked adrenoleukodystrophy (X-ALD) is a rare (incidence of 1:17,000 37), progressive neu-
rodegenerative disease which affects cerebral white matter, peripheral nerves, adrenal cortex
and testis 35 that typically strikes boys aged 3 to 14. It is caused by mutation in the ABCD1
gene that codes for a peroxisomal transporter 40,4. Biochemically the disease is characterized by
elevated plasma and tissue levels of the saturated very long-chain fatty acids (SVLCFAs) C24:0
and C26:0 36.
As described in Section 1.2.2, we model the effect of Lorenzo’s Oil (LO) administration on
the change in C26:0 plasma concentration in boys suffering from X-ALD. We also adjust for
various covariates specific to individuals and observations, namely the dose of LO administered,
the weight of the patient, etc. As mentioned, administration of LO is known to increase levels
of erucic acid in the plasma. Several papers have shown that erucic acid can normalize C26:0
plasma levels within 4-6 weeks3,48. However, little has been done to establish its clinical efficacy
or indications for its use 1. Although several open-label clinical trials (i.e., trials where both
the researchers and participants knew which treatment was being administered) were unable
to establish the clinical benefit of LO in patients with childhood cerebral adrenoleukodystrophy
(CCALD) 2,56, other studies have indicated that LO can prevent CCALD when treatment is
administered prior to cerebral involvement 39,38, and there are also indications of a benefit in
the smaller adult subpopulation 27.
Hence our broad action plan for modeling can be summarized as:
LO
PK−→ Erucic Acid Concentration PD−→ change in C26 level−→Brain MRI abnormalities
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In this diagram, the first link is captured by the PK modeling, while the second involves PD
modeling, both of which we discuss below. Our Phase IIa design will permit us to hone in on a
rationally-derived LO dose that accounts for both toxicity and efficacy (here, measured by the
improvement in biomarker response).
We had access to data on 130 subjects screened for the study at the John Hopkins Research
Hospital from 2000 to 2014 under an expanded access trial (ClinicalTrials.gov, NCT02233257).
As noted, the diagnosis of X-ALD was confirmed by plasma SVLFCA assay. Fourteen subjects
with incomplete data (i.e., missing either dose, or erucic acid, and/or C26:0 concentrations)
were excluded from the study, resulting in n = 116 subjects for analysis who were followed until
they developed any brain MRI abnormality. All participants received a daily dose of 2-3mg/kg
of LO, a dose calculated to provide roughly 20% of caloric intake, along with maintaining some
dietary restrictions.
Blood samples were collected at baseline as well as every month for the first 6 months,
followed by collection at 3- to 6-month intervals after LO administration. The samples were
processed and plasma was analyzed to obtain a fatty acid profile (FAP) for 70 fatty acids,
including C26:0 and erucic acid. From the 116 subjects, 2384 paired C26:0 and erucic acid
concentrations were available to develop the PD model. Hence we have multiple observations
per patient, but only one observation per patient per visit. Usually in pharmacokinetic studies,
we have data from samples collected at various time points after the drug was administered.
This makes tasks such as deriving the half life of the drug, required for rational drug dosing
strategies, straightforward. In our case we have only one observation per LO intake. With this
less rich type of data, we must make more heroic assumptions in order to estimate the drug’s
half life.
3.2 Hierarchical Bayesian PK/PD Modelling
3.2.1 The Pharmacokinetic Model
Let Y denote the erucic acid concentration, and Z be the C26:0 level obtained from the FAP.
We also have each patient’s weight in kg, denoted here as wt, taken at each reading. For any
drug, the average steady state concentration (css) can be written as the dosing rate divided by
the clearance, which is the volume of the drug cleared totally from the blood (in our case, erucic
acid) per unit time 9. Our erucic acid observations (which we assume are at steady state) are
actually comprised of two parts: the endogenous part (i.e., erucic acid produced by the body
itself) and the exogenous part (erucic acid coming from LO administration). Hence for the jth
observation on the ith patient, where i = 1, ..., 116 and j = 1, 2, ....ni, we model clearance using
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allometric scaling as
clearance erucicij = θ1
(
weightij
70
) 3
4
. (3.1)
Since the dose was given in terms of ml, we need to multiply it by the density of erucic acid,
which is 0.860 g/ml (and therefore 860 mg/ml). Thus Rate erucicij =
860×Dose
24 . Next let
cssexij = Rate erucicij/clearance erucicij , where cssex denotes the exogenous css. We
assume erucic acid concentration is at steady state. Let cssav denote the average steady state
concentration, cssavij = cssexij + endo erucici , where endo erucici denotes the endogenous
css for patient i. We model the observed css Y as this cssav plus some random Gaussian error.
Hence in statistical modeling terms, for Yij , the level of erucic acid observed in the FAP analysis
of the jth sample on the ith patient, we have
Yij = cssavij + (errorije
η3i) , (3.2)
where errorij = cssavij1ij and 1ij ∼ N(0, σ21) .
Incorporating subject-level variability and utilizing equation (3.1), we obtain
clearance erucicij = θ1
(
weightij
70
) 3
4
eη1i and endo erucici = θ2e
η2i ,
where ηki
indep∼ N(0, ω2k) for k = 1, 2, 3, the number of subject level errors we include in our
model, θl ∼ N(µl, τ2l ) for l = 1, 2, and we put a vague Gamma(0.1,0.1) prior on 1σ21 .
3.2.2 The Pharmacodynamic Model
The Emax model is a nonlinear model frequently used in pharmacodynamic dose-response
analyses. In this set up, the basic model is
Responseij = E0 − Emaxi ∗ cssexij
EC50i + cssexij
, (3.3)
where Emax denotes the maximum effect attributable to erucic acid concentration, EC50
denotes the erucic acid concentration that produces half of Emax, and E0 is the basal effect,
corresponding to the patient response when the erucic acid concentration is zero 32. Since in
our case the effect is decreasing with increasing concentration of the drug, we will use the minus
sign55,54 in equation (3.3). The observed effect is this response plus some error. Converting to
a statistical model, for Zij (the level of C26 observed in the FAP analysis) we have
Zij = (C26endoi − Effectij)(1 + 2ij) , (3.4)
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node prior sd mean posterior sd MC error 2.5% median 97.5%
σ1 0.002215 6.269E-5 8.32E-7 0.002093 0.002215 0.002341
σ2 4.438 0.1509 0.003391 4.145 4.435 4.742
θ1(clearance) 5 31.0 0.6158 0.01766 29.82 30.99 32.22
θ2(endoerucic) 0.1 0.6083 0.1003 0.003036 0.4162 0.6139 0.8022
θ3(Emax) 0.1 0.4573 0.02572 0.002346 0.3968 0.4591 0.5105
θ4(EC50) 10 0.8931 0.6321 0.04938 -0.1921 0.8446 2.207
θ5(C26endo) 0.1 0.8822 0.02605 0.002383 0.8256 0.8848 0.9313
Table 3.1: Table depicting parameter estimates obtained from the model described
where 2ij
iid∼ N(0, σ22). To add subject-level variability to our model, we can extend (3.3)
by defining Emaxi = θ3e
η4i , EC50i = θ4e
η5i , and in (3.4) we can also assume C26endoi =
θ5e
η6i . As in the PK model, ηki
indep∼ N(0, ω2k) for k = 4, 5, 6, the patient-level errors we include,
and θl ∼ N(µl, τ2l ) for l = 3, 4, 5. Finally, we again add a vague prior, 1σ22 ∼ Gamma(0.1, 0.1)
Using the data in hand, we seek to fit our Bayesian hierarchical model with some vague and
some informative priors in an attempt to estimate all the unknown quantities. We also choose
appropriate scales for the error components, both at the individual and observational levels. Our
software platform is WinBUGS31, which uses Markov chain Monte Carlo (MCMC) 8 methods to
sample from the joint posterior distribution of all unknown model parameters.
3.2.3 Results for the LO PK/PD Data
After trying various modifications, due to weak identifiability the model converged best with
no individual level errors, i.e., no ηki terms. Our MCMC approach requires us to assign some
starting values for the θli, l = 1, ..5, and also the σ
2
m, m = 1, 2. We used crude estimates of
these parameters derived from the data using NONMEM; see also Moser et al39. Specifically,
we used 1
σ21
= 3, 1
σ22
= 43, θ1 = 42, θ2 = 0.5, θ3 = 0.655, θ4 = 3.34, and θ5 = 0.971.
The resulting parameter estimates are given in Table 3.1, with corresponding fitted PK and
PD curves shown in the left and right panels respectively of Figure 3.1. The prior and posterior
standard deviations as given in the second and fourth columns are very different for θ1, θ3, θ4
and θ5, indicating that the data were able to inform these posteriors. In particular, the posterior
for θ3 reveals that the average maximal effect of erucic acid is fairly precisely estimated at 0.46
(95% BCI 0.40 to 0.51), and the estimated posterior median erucic level required to produce
half of this maximal effect is only 0.84. These values are consistent with the fitted PD curve
plotted in the right panel of Figure 3.1, where we replace all individual level parameters in (3.4)
with their population level estimates. This plot also shows a scatterplot of the calculated cssex
versus Zij for each observation, a solid line showing the fitted model, and a dashed line depicting
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Figure 3.1: Left panel: plot of the PK data (Yij vs. estimated cssavij) along with the fitted
regression line, which has slope 1.059; right panel: plot of the PD data (Zij vs. estimated
cssexij) along with the fitted Emax curve.
a loess smooth of the data. The fit in both cases is far from perfect, in particular due to the
missing information in the interval 0 < cssex < 7. For larger cssex, the scatterplot has points
that are dispersed far away from the fitted lines, perhaps indicating an increasing residual error
variance with increasing cssex.
In order to see how sensible our PK estimates are, the left panel of Figure 3.1 offers an
exploratory plot. If our estimates of the θ’s are good, then according to (3.2), if we plot
Yij vs cssavij , the resulting regression line should have slope approximately 1. Here cssexij is
calculated using our estimated θˆ1, and endo erucicij is the Yij value corresponding to Dose = 0.
For individuals with no Dose = 0 measurement, we take cssavij = cssexij + θˆ2, where θˆ2 is
the estimated posterior mean. The left panel of Figure 3.1 actually shows this plot without
a few extremely outlying patients (discarding 69 of the 2558 observations), and also omitting
observations with dose = 0. We obtain a fitted slope of 1.059, in agreement with our model.
Thus, though our PK data are much less informative than our PD data, the Bayesian approach
still permits refinement of our prior opinion.
3.3 Phase IIa Design
3.3.1 Approximate Linear PD Model
Having investigated the basic PK and PD properties of LO, we now proceed to design a basic
Phase IIa trial to determine the toxicity and efficacy response of a few candidate dosing regimes.
Consider n patients recruited in a clinical trial having a total duration of J biweekly periods
(“bi-weeks”). We first record Zi0, the observed C26 level for patient i at baseline, assuming
that all participants have no exogenous erucic acid in their bodies at this time (perhaps after
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a “washout” period) for i = 1, ..., n. At each bi-week j = 1, ..., J , we administer a daily dose
of the drug to patient i that produces an erucic acid steady-state concentration of cij . We
consider five values for cij : 0, 5, 10, 25 and 35. Hence when we say “a dose level of 5”, we
mean a dose large enough and given often enough to produce cssex = 5 for that particular
patient. These cij levels were chosen based on the right panel of Figure 3.1, which indicates
a meaningful reduction in Z for cssex as low as 5. As the trial takes place, we observe Zijk,
the C26 level for the ith patient in the jth period on the kth day, k = 1, ...,Kij (where Kij will
typically be 14).
Next we define Xij = Zi0−
Kij∑
k=1
Zijk
Kij
, the average improvement in C26 level for patient i in
period j. For simplicity, in our initial trial design algorithm we assume Xij |θij , σ2x ∼ N(γij , σ2x),
and further assume
γij = µ
e
i + βecij , (3.5)
where µei ∼ N(µe, σ2µe) and the “e” superscript denotes efficacy. That is, for the moment
we assume C26 improvement is linear in erucic acid concentration, with every person hav-
ing their own baseline improvement parameter, µei . Adding the vague hyperprior distributions
βe ∼ Uniform(−1, 1) and σ2x ∼ InverseGamma(0.1, 0.1) complete the efficacy model speci-
fication. Intuitively, if no dose is given, E(Xij) = µ
e
i should be zero, since we are assuming Zi0
is the C26 level at baseline (pre-LO). Hence we assume the true values µe = 0 and σ2µe = 1.
We assume toxicity outcomes to be binary variables (e.g., presence or absence of elevated
platelet count in the blood, or bone marrow suppression) for each patient every bi-week, i.e.,
Wij = 1 if toxicity was observed and 0 if no toxicity was observed. We assume that piij , the
probability of observing a toxicity for patient i during bi-week j, is such that
logit(piij) = µ
t
i + βtcij , (3.6)
where “t” denotes toxicity, and we now assume the linearity of the logit of the toxicity probability
in cij . We assume µ
t
i ∼ N(µt, σ2µt) and βt ∼ Uniform(0, 1), so each individual has their own
personal propensity for toxicity, and the drug cannot reduce toxicity. A simple calculation shows
that µt = −4 delivers piij = 0.01 at cij = 0. In what follows, we therefore assume the true
values µt = −4, and σ2µt = 0.3. We also experiment with µt = −2 to check robustness of our
method to this assumption.
Finally, to introduce correlation between the efficacy and toxicity responses, we can instead
assume the following joint model for the subject level effects:(
µei
µti
)
∼ N2
((
µe
µt
)
, Σ
)
, (3.7)
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Is P (piij > pit|XjWj) > PToxU ?
yes no
Assign dose
level 0 for
patient i.
Is P (piij > pit|XjWj) > PToxL ?
yes no
Reduce dose
level one step
for patient i.
If dose level =
0, stay at 0.
Is P (γij > θe|XjWj) > PEffU ?
yes no
Stop trial
for patient
i and assign
curent dose
as final dose.
P (γij > θe|XjWj) > PEffL ?
yes no
Assign
ci,j+1 = ci,j ,
i.e. repeat the
current dose
for the patient.
Assign ci,j+1
the next higher
dose level.
Figure 3.2: Dosing algorithm for Phase IIa trial design, patient i, bi-week j ≥ 4.
where Σ takes the form
(
σ2µe ρσµeσµt
ρσµeσµt σ
2
µt
)
. We put a modestly informative Wishart(Ω, 20)
prior on Σ, and assume Ω =
(
100 0
0 0.02
)
to preserve the imbalance in the scales of σ2µe and σ
2
µt .
Setting ρ = 0.7 and letting Xj and Wj denote all the efficacy and safety data, respectively,
observed up to bi-week j, our dosing algorithm for the ith patient at bi-week j is given in
Figure 3.2. Note that our design is based entirely on posterior exceedance probabilities for toxicity
(piij) and efficacy (γij), where we use the thresholds P
Tox
U = 0.8, P
Tox
L = 0.2, P
Eff
U = 0.9,
and PEffL = 0.4. We selected threshold values of pit = 0.6 for toxicity and θe = 0.8 for efficacy
based on clinical and practical considerations; below we check to make sure they deliver a design
with acceptable operating characteristics.
To ensure adequate data before the trial’s adaptive phase, we assign the starting dose
(cij = 5) to all patients i for bi-weeks j = 1, 2, 3. Beginning with bi-week j = 4, we cycle
through the flowchart in Figure 3.2 for each patient i and bi-week j, noting the dose level where
each patient stopped due to high efficacy at the current dose level.
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3.3.2 Emax PD Model
In this section we incorporate the Emax model we used in Subsection 3.2.2 into our Phase IIa
design. In the design utilized in Section 3.3.1, we assumed an approximating linear PD model
for the efficacy of Lorenzo’s Oil. While this was computationally convenient for our design
calculations, the right panel of Figure 3.1 suggests the relationship may be nonlinear. Therefore,
in this section we return to model (3.3), estimated from the FAP data in Section 3.2.3. Since
in our design we are estimating the difference of C26:0 from baseline, we replace (3.5) with
γij =
θ3cij
θ4i + cij
,
where as before θ3 and θ4i correspond to the Emax and EC50 parameters, respectively, and
cij again denotes the steady state erucic acid concentration for subject i during bi-week j. By
analogy with µei , each subject is allowed to have his or her own EC50 parameter. We adopt the
priors θ3 ∼ Normal(µ3, σ2µ3) and θ4i ∼ Normal(µ4, σ2µ4), and also select the vague hyperprior
distributions µ3 ∼ Uniform(−10, 10) and µ4 ∼ Uniform(−10, 10). We assign σ2µ3 = 1 and
σ2µ4 = 1. Clearly θ3 now drives the efficacy of LO, just as βe did in our earlier design (3.5).
To begin with, we set βt = 0.15 and assume no correlation between the efficacy and toxicity
parameters, θ4i and µ
t
i, although one could model such correlation using a bivariate normal prior
as in (3.7). In what follows, toxicity is simply defined as in the previous subsection according to
(3.6), where we assume µti ∼ Normal(µt, σ2µt) independently of the θ4i, and where µt = −4
and σ2µt = 0.3. Our dosing algorithm remains the same as given in Figure 3.2, but where now
P ToxU = 0.9 and P
Tox
L = 0.5. In our Emax model, the efficacy and toxicity models are assumed
independent of each other, though the cut-offs have not changed (i.e., pit = 0.6 and θe = 0.8).
3.3.3 Phase IIa Emax Simulation Results
Our simulation results are based on a trial of J = 12 bi-weeks, various values of βt, Σ as defined
in the previous section, and use L = 1000 simulated datasets for each combination of n and βe.
For the `th simulated dataset, where ` = 1, ..., L, we first generate Xij and Wij for all patients
in each of the bi-weeks j = 1, 2, 3. Next, for bi-week j = 4, ..., J , we first generate Xij and Wij
for the current bi-week and calculate the posterior estimates using Xj and Wj (i.e., all Xim
and Wim for m = 1, ..., j). Based on the posterior estimates for bi-week j, we run through the
dosing algorithm to determine the dose for each of the patients for bi-week j+ 1. Finally at the
end of the J th bi-week, we obtain the posterior 95% equal-tail Bayesian credible interval (BCI)8
for βe. The power of the trial is estimated as the proportion of times among the L simulated
datasets that the 95% BCI for βe does not include 0 (since in our procedure this corresponds
to rejecting H0 : βe = 0).
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Figure 3.3: Plot depicting the power curve for the Emax model at each value of n with increasing
θ3 for θ4i = 0.8931 and µ
t = −4 (low overall toxicity) and βt = 0.15 (low drug toxicity).
For all subjects i, we assume θ4i = 0.8931, the estimate of θ4 obtained in Section 3.2.3. We
study the Type I error and power for varying values of n and θ3, to give us an idea as to the
operating characteristics of our design.
In spite of the nonlinearity introduced by the Emax model, trial operating characteristics
remain reasonable. Table 3.2 provides some results under various choices of efficacy and toxicity
parameters. The Type I errors (corresponding to θ3 = 0) are consistently around 0.05, and the
power seems to escalate fairly quickly to desirable levels with increasing θ3; see Figure 3.3 for
power curves in the case where βt = 0.15 (low drug toxicity). The θ3 estimated in Section 3.2.3
is approximately 0.5, for which the power here is almost 1 even for n as small as 10. Similar
simulations with the linear model also lead to reasonable operating characteristics slightly weaker
than in the Emax model. Although the Emax model does perform well, it runs much more slowly
than the linear model. Hence to the extent that the linear model can be thought of a good
approximation to the true efficacy curve, opting for the linear model will lead to much faster
computations. Certainly the right panel of Figure 3.1 offers little justification for either model,
offering possibly more support for the simpler alternative.
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As can be seen in Table 3.2, for θ3 = 1 cases shown when βt = 0.15, the high assured
efficacy of LO means more patients are responding very well and hence don’t need to take a
high dose (25 or 35). Also, on increasing the toxicity to βt = 0.3 or = 0.5, we see fewer or even
no patients being assigned to the higher doses, no doubt due in part to the flatness of the fitted
Emax curve for larger LO doses.
3.4 Discussion
In Section 3.2 we successfully fit a hierarchical Bayesian model to obtain sensible PK/PD es-
timates for LO that can now be used to comprehend its clinical characteristics. We were then
able to design an adaptive Phase IIa trial to evaluate LO while taking into account the effect of
the treatment on each individual both in terms of efficacy and toxicity. In future this can serve
as a safer trial for pediatric patients, and also produce reliable results. We were also able to
base our Phase IIa model on the PK/PD of LO, which not only led to a more justifiable model
but also can be used to update the PK/PD parameters during the course of the trial as more
data are obtained to get a better understanding of LO. Further discussion and future work in
this area is elaborated in Chapter 5.
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n βt θ3 power dose=0 dose=5 dose=15 dose=25 dose=35
10 0.15 0 0.049(0.007) 0.1 0.06 0.21 0.34 0.29
0.2 0.503(0.016) 0.1 0.07 0.21 0.35 0.27
0.5 0.998(0.001) 0.1 0.07 0.2 0.36 0.27
1 1(0) 0.01 0.55 0.29 0.13 0.03
20 0 0.049(0.007) 0.1 0.07 0.23 0.32 0.28
0.2 0.0792(0.009) 0.1 0.07 0.23 0.32 0.29
0.5 1(0) 0.1 0.07 0.22 0.32 0.29
1 1(0) 0 0.6 0.28 0.1 0.02
40 0 0.047(0.007) 0.09 0.06 0.25 0.32 0.28
0.2 0.966(0.006) 0.09 0.07 0.24 0.32 0.28
0.5 1(0) 0.09 0.06 0.25 0.31 0.28
1 1(0) 0 0.71 0.23 0.05 0
10 0.3 0 0.072(0.008) 0.25 0.36 0.28 0.11 0
0.5 0.998(0.001) 0.25 0.35 0.28 0.12 0
20 0 0.048(0.007) 0.27 0.34 0.27 0.12 0
0.5 0.5(0.016) 0.28 0.34 0.25 0.12 0
40 0 0.055(0.007) 0.31 0.32 0.26 0.11 0
0.5 1(0) 0.31 0.32 0.26 0.11 0
10 0.5 0 0.05(0.007) 0.48 0.16 0.35 0 0
0.5 0.991(0.003) 0.47 0.17 0.36 0 0
20 0 0.054(0.007) 0.51 0.19 0.3 0 0
0.5 1(0) 0.5 0.19 0.3 0 0
40 0 0.046(0.007) 0.5 0.19 0.31 0 0
0.5 1(0) 0.5 0.2 0.3 0 0
Table 3.2: Estimated power (standard error) of the Phase IIa design (column 4) and proportion
of patients being assigned to each dose (columns 5-9) using the Emax model for various choices
of θ3, βt, and n at µ
t = −4 and θ4i = 0.8931 for all i.
Chapter 4
PK/PD Data Extrapolation Models
for Improved Pediatric Efficacy and
Toxicity Estimation
4.1 Introduction and Motivating Dataset
As discussed in Section 1.2.3, secondary hyperparathyroidism (HPT) is a serious and frequently
encountered problem in both pediatric and adult patients with chronic kidney disease (CKD)
on dialysis. Secondary HPT is characterized by persistently elevated blood level of parathyroid
hormone (PTH) levels caused by the release of excess amounts of PTH from enlarged parathyroid
glands. The parathyroid glands are a component of a feedback loop that maintains blood calcium
concentrations within a tight normal range17. Parathyroid hormone (PTH) secretion is increased
in response to low calcium concentrations, and, alternatively, high calcium levels will turn off
the secretion. The goals of treatment for secondary HPT in both children and adults include
efforts to reduce the abnormally high concentrations of iPTH that characterize the disorder.
As discussed briefly in Section 2.3 cinacalcet is an oral calcimimetic agent that increases the
sensitivity of the calcium-sensing receptor to extracellular calcium41,42. Cinacalcet is indicated
for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney
disease (CKD) on dialysis. It is not currently approved for use in children, though the drug maker,
Amgen, is currently suing the FDA in an attempt to obtain six months of pediatric exclusivity
for its use in children. Amgen is accusing the FDA of violating the Administrative Procedure
Act by denying pediatric exclusivity, as well as by depriving the company of its Fifth Amendment
right to due process22. Based on the understanding that the pathophysiology and progression
of the disease, the role of the the calcium-sensing receptor, and the mechanism of action of
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cinacalcet are similar in adults and children, the clinical rationale for using cinacalcet to lower
elevated PTH concentrations in pediatric secondary HPT patients is considered similar to that of
adult patients. Reduction of iPTH levels following treatment with cinacalcet may be associated
with reduction in corrected calcium (cCa) levels, sometimes below the normal range, resulting
in safety concerns.
In pediatric settings, it is extremely crucial that we are parsimonious with the patients re-
cruited for experimentation, as pediatric settings pose myriad economical, logistical and ethical
challenges 6,15,26. The US federal government has taken action to promote research in these
fields through various legislative actions. FDA has also promoted modernization of drug ap-
provals through its Critical Path Initiative, and has issued guidance documents on extrapolating
historical data of adults in pediatric trials for medical devices12. In particular, Bayesian statistical
methods have been suggested as sensible ways to borrow information from adult trials, potentially
allowing us to arrive at more reliable results even with relatively small pediatric datasets5,8,30.
As seen above, various statistical methods exist for measured borrowing from existing historical
datasets, including power priors25 and commensurate priors18. However, the proper amount of
information to borrow in any given situation (where the quality and commensurability of the
adult information may be in doubt) remains difficult to determine.
In most regulatory settings, the usual approval process is preceded or accompanied by ex-
tensive studies to understand the drug’s pharmacokinetic (PK) and pharmacodynamic (PD)
properties. Yet in practice, although the PK/PD results are used in scale-up to support the
determination of appropriate doses, these detailed data are not directly used in the confirmative
trial setting. In this case, the PK/PD work is performed, checked, and then used to moti-
vate subsequent studies of clinical safety and efficacy, but the degree of similarity between the
PK/PD properties seen in children and adults is not explicitly used in the subsequent pediatric
development program.
In this chapter, we attempt to utilize the rich PK/PD data to inform the amount of borrowing
of information from adults during the later clinical phases of drug development. The basic
idea here is that if the PK/PD properties of the drug are similar in adults and children, this
helps justify borrowing more liberally from the adult data in clinical endpoints of the pediatric
development program. PK/PD modeling is a well-understood and well-studied area in drug
development, and FDA has also issued extensive guidance on these topics13. We will use
hierarchical modeling of the clinical cinacalcet PK/PD data to quantitatively assess the similarity
between adults and children, and use this information in various borrowing rules of clinical
endpoints whose statistical properties can then be evaluated.
The remainder of this chapter unfolds as follows. In Section 4.2, we describe how we use
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nonlinear mixed-effects (NLME) modeling to analyze the combined early pediatric and adult
PK/PD data to determine the similarity of the PK/PD model parameters between the two
groups. The NLME modeling (often referred to as a population PK/PD approach) is widely
accepted in drug development as a tool to identify the pharmacostatistical characteristics of
a pharmacological system. We then describe an approach for using measures of adult-child
PK/PD similarity to inform a power prior model for combining subsequent adult and child data.
Section 4.3 does this in the context of longitudinal efficacy data, while Section 4.4 extends our
modeling to handle joint estimation of both efficacy and toxicity, again informed by the PK/PD
results. Throughout we illustrate our approaches in the context of clinical trials of cinacalcet
for treating pediatric secondary HPT, where we monitor both iPTH (efficacy) and cCa (safety)
levels. After analyzing these data, we simulate the bias and mean squared error properties of our
proposed procedure across a range of adult-child simulation scenarios in Section 4.5. Specifically,
we simulate data with different levels of similarity between adults and children in each scenario.
In Section 4.6 we offer an alternative model to describe the efficacy and toxicity of the drug
using a piecewise model for the longitudinal data. We finally conclude the chapter with a brief
discussion in Section 4.7.
4.2 PK/PD Modeling
We begin with a population-based NLME approach to develop a single PK/PD model that
describes our observed concentration-time and effect-time data in pediatric and adult patients.
The full model includes separate parameter estimates for adults and children, but can be reduced
to a more parsimonious model where some parameters can be shared between the two groups.
Our conceptual PK/PD model is pictured in Figure 4.1. The PK side (lower section) assumes
linear PK and contains a dosing compartment with a first-order absorption process, a central
compartment from which cinacalcet concentrations are measured that has first-order elimina-
tion, and a rapidly distributing peripheral compartment. The PD side (upper section) assumes
a simple turnover model in which cCa is produced physiologically at a zero-order rate and is
eliminated under a first-order process. These sections separately allow for drug concentrations
to increase and decrease with each dose, and cCa to be at a baseline steady-state concentration
when no cinacalcet is present. A novel semi-mechanistic allosteric activation model (to be the
subject of a future manuscript by Amgen pharmacometric staff) accounts for the physiological
feedback between iPTH and cCa. In this model, cCa production is stimulated by increases in
iPTH from baseline, while iPTH production is directly inhibited by changes in CaR receptor oc-
cupancy by the innate ligand, ionized calcium, relative to the baseline (no cinacalcet treatment)
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Compartment
No. 3: Peripheral
Compartment No. 2: CentralCompartment No. 1: Depot
Compartment No.
4: Ionized Calcium
Figure 4.1: The four compartment structure assumed by the cinacalcet PK/PD model.
occupancy. The NLME modeling required is now fairly routinely implemented in software pack-
ages such as NONMEM (www.iconplc.com/innovation/nonmem/), which has become as standard
in the pharmacological modeling community as BUGS has become for Bayesians.
In modeling PK-PD data, a choice must be made to analyze the PK and PD data simul-
taneously or sequentially28,47,59,60,61. Simultaneous modeling may be considered optimal from
a hierarchical Bayesian point of view, but PD models are often highly complex (here, involving
systems of differential equations), so even computing joint maximum likelihood estimates can
be numerically difficult. Furthermore, we are more certain of the descriptive nature and pre-
cision of measurements in our PK models than our PD models, which means a simultaneous
PK/PD approach risks the possibility of the PD side of the model misinforming our PK esti-
mates. Hence, we chose to model these data sequentially. Specifically, the PK data were first
modeled, and the empirical Bayes estimates of each individual’s PK parameters were then used
to generate predicted concentration-time profiles that together with the PD data help specify
the PD parameter estimates.
In our setting, the PK/PD information consists of data from 7 clinical studies, 3 of which are
adult studies as described in Section 1.2.3. Data from the aforementioned 7 studies were pooled
and analyzed using NONMEM Version 7.3. Subjects who had no PK or PD concentrations
available, or had screening failure even when PK or PD concentration or dosing records exist,
were not included in the population PK/PD database. Any cinacalcet PK concentrations before
the first dose administration were also excluded from the analysis, as were any cinacalcet PK or
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PD concentrations below the quantification limit of the bioanalytical assay.
In this paper, our semimechanistic PD model features six key fixed effects θl, l = 1, ..., 6,
with corresponding random effects ηli for the i
th patient, whose effect is modeled as θli =
θle
ηli . As previously stated, a novel three-compartment PK model was fit to the cinacalcet
concentration data. This part of the analysis, the details of which will be the subject of a
subsequent publication, provided empirical Bayes estimates of the individual PK parameters,
which were then entered into the data set as fitted random effects. This produces patient-
specific predicted cinacalcet concentrations that are then available to drive the PD response.
The six PD parameters were initially permitted to have different values for adults and children
(i.e., 12 parameters). Adding in the model’s two variance parameters (for observation- and
patient-level variability), we have a 14-parameter model that we refer to as Model 1. However
this model suffered from poor NONMEM convergence.
Therefore, fitting Model 2 we set two of the six parameters to be the same for adults and
children, resulting in a 12-parameter model. This model successfully converged with an objective
function value (OFV, a goodness of fit metric similar to a sum of squares) not significantly
different from that of Model 1 using a likelihood ratio test (p > 0.05 using the usual χ2 statistic
with df=2). However, when we set all six main effect parameters equal for adults and children
(Model 3, an 8-parameter model), now the difference in fit between this model and Model 2 is
statistically significant. Specifically, OFVModel2 − OFVModel3 should follow a χ2 distribution
with 12− 8 = 4 degrees of freedom. For our data, this produces a p-value of p = 0.002. Thus,
we have evidence that some, but not all of the PD model parameters can be safely assumed to
be the same for adults and children, with a statistically significant gap between what might be
thought of as “the full model” (Model 2, which converges and fits well) and “the null model”
(Model 3, which erroneously assumes no differences at all between the adult and pediatric model
fits). We emphasize that this p-value corresponds to a valid statistical test, but not one that
the PD experiment was designed to run.
We suggest using some scale multiple of this p-value (say, Kp for some K > 0) as a sensible
power (λ) in a power prior model for the clinical data. Specifically, K might be chosen to
produce an adult EHSS that regulatory authorities do not find unacceptably large (say, many
times larger than the actual pediatric sample sizes involved). Various EHSS definitions exist,
but we can use definition (2.12) provided in Chapter 2 for a parameter of interest ξ namely
EHSS(ξ) = nc
[
V ar−1(ξ|Xc, Xa, λ)
V ar−1(ξ|Xc, λ) − 1
]
, (4.1)
which is the percent improvement in ξ’s posterior precision (inverse variance) arising from using
the chosen fraction of the adult data, expressed on the same scale as the child sample size.
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Note that other metrics (e.g.,
√
V ar−1) might have been chosen in (4.1), and that the answer
will vary with the choice of ξ.
It may be useful to specify a target function to map the obtained p-value to an EHSS (or
its ratio to the pediatric sample size nc). These targets can be used by the drug developers as
well as the regulatory authorities to specify how much adult information they are comfortable
borrowing, and on what scale. We then run our hierarchical models for the longitudinal analysis
with different degrees of adult data borrowing, and pick the one that results in a sufficiently
close EHSS. The target function used in this chapter is
f(p) = Ψ× pα , 0 < α < 1. (4.2)
In this function Ψ will dictate the scale for the range of the function and we may choose it to suit
our interpretative need. For example, taking Ψ = EHSS would relate p to the total effective
number of adults borrowed, whereas Ψ = EHSS/nc would control the ratio of effective adults
borrowed to the pediatric sample size. Figure 4.2 plots this function for a few sensible candidate
values of α, all between 0 and 1 since the target should increase rapidly for smaller p and dampen
as p becomes larger. The numerical scales here pertain to our cinacalcet clinical data sample
sizes, which we describe in Section 3 below.
4.3 Hierarchical Modelling of Clinical Efficacy Data
Having measured the adult-child similarity in the PK/PD data, we turn to the longitudinal clini-
cal data from adult and pediatric clinical efficacy studies of cinacalcet, in the context of a linear
mixed effects Bayesian hierarchical model to study the drug’s effect on iPTH. As discussed in
Section 1.2.3, these data came from three adult Phase III clinical studies with subjects aged at
least 18 years with secondary HPT receiving dialysis, and one pediatric Phase III study. Reca-
pitulating, the adult studies have similar study designs and were randomized, placebo controlled
clinical trials. Total sample size in these adult studies is N=1136. The pediatric data were
collected from the 30-week, double-blind, placebo-controlled phase of the pediatric study. The
study enrolled N=43 subjects aged 6 to 18 years with secondary HPT receiving dialysis. During
the course of the studies, a cinacalcet dose was given daily, and labs including iPTH and cCa
were measured every two weeks. In this chapter, we fully utilize the longitudinal information in
the iPTH data collected during the whole study to evaluate the effect of cinacalcet in lowering
iPTH level over time.
Many extrapolation techniques10 have been suggested and used to streamline rare or pe-
diatric drug development and thus speed approval of drugs for labeling. FDA also has issued
guidance documents on borrowing of adult information for pediatric studies involving devices12.
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Figure 4.2: Plot of the target function f(p) for various values of α. The right vertical axis
corresponds to Ψ = EHSS while the left vertical axis corresponds to Ψ = EHSS/nc using the
sample sizes from our cinacalcet data.
37
However, borrowing information in the case of drugs is not as straightforward, in no small part
because, unlike devices, drugs may well have PK and PD properties that differ between adults
and children,51 exactly the information we seek to incorporate in this chapter.
Based on the half-life of cinacalcet, a period of 7 days off treatment is expected to result in
plasma levels of cinacalcet that do not have a pharmacodynamic effect. Thus data collected 7
or more days after the last dose date were excluded from the analyses. After this truncation of
data, the number of patients with post baseline data in the pediatric dataset is nc = 42, and
na = 1107 in the adult studies. Let Xi,j be the percent change from baseline in the iPTH level
of patient i (i = 1, ..., nc, ..., (nc+na)) in the week of the patient’s j
th observation, j = 1, ...,mi
(where mi varies from 3 to 25). That is:
Xi,j =
ipthi,j − baseline ipthi
baseline ipthi
× 100 .
This percentage change will be our outcome variable in the linear model. Let ti,j denote the
week for the jth observation on the ith patient. This model for the pediatric group is
Xci,j ∼ Normal(µc,pthi,j , 1/τ ce ), i = 1, ..., nc, (4.3)
where µc,pthi,j = µ
c
1it
c
i,j + I(drug
c
i = 1)(µ
c
dt
c
i,j) .
Our model specifies a linear relationship between the percent change from baseline in iPTH and
time, where a negative slope indicates an effective treatment. Since by definition, the percent
change from baseline is 0 at time point 0, there are no intercept terms in the pediatric or
adult models for efficacy. Here, the µc1i are subject-level random effects, assumed a priori to
independently follow a Student’s t3(η
c
0, τ
c
η) specification, where η
c
0 is assigned a flat prior and τ
c
e
is assigned a vague Gamma(0.1, 0.1) prior. Since Xcij is a percent change of a quantity (iPTH)
that takes only positive values, it cannot go below −100, but its upper limit is ∞. We expect a
few extremely large outlying patient trajectories, justifying replacing the usual normal random
effects distribution with the heavier-tailed t3 to limit bias.
Similarly for the adults, we assume
Xai,j ∼ Normal(µa,pthi,j , 1/τae ), i = 1, ..., na,
where µa,pthi,j = µ
a
1it
a
i,j + I(drug
a
i = 1)(µ
a
dt
a
i,j) ,
where µa1i are the subject-level random effects, assumed to independently follow a t3(η
a
0 , τ
a
η )
specification. Similar to the child model, we assign a flat prior to ηa0 and a vague
Gamma(0.1, 0.1) prior to τae .
As mentioned above, a natural approach for Bayesian borrowing of strength from an auxiliary
dataset is through the power prior model, as described for instance by Ibrahim and Chen25. We
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begin by assuming that ηa0 = η
c
0 = η0 and µ
a
d = µ
c
d = µd. We then obtain the posterior
p(µd|Da, Dc) as proportional to L(µd|Dc)L(µd|Da)λpi(µd). Note that λ controls how much
information will be borrowed from the auxiliary (adult) data to supplement the fully-utilized
child data. As suggested by our earlier PD analysis in Section 4.2, since the p-value of the test
comparing the “full”(adult and child parameters estimated separately) and “null” (adult and
child parameters all identical) PD models provide a measure of the dissimilarity of the adult and
child PD processes, we select λ = Kp for some K > 0, where choice of K may be informed
by our target function (4.2) and the resulting EHSS19. Under this approach that utilizes the
p-value we allow our measure to be influenced by the sample size which could be a drawback
hence we could use other approaches to arrive at our similarity measure such as those discussed
in Section 4.7.
For fixed power priors, there is a one-to-one relationship between the power parameter and
EHSS (though of course our MCMC-based estimates of the latter will be subject to error).
The relationship is particularly straightforward in the normal likelihood setting; see for example
Morita et al.33,34 and Penello and Thompson45. In our case, we take the overall fitted slopes in
the placebo group, η0, and the drug group, η0 + µd, as our parameters of interest ξ.
In this chapter we use Ψ = EHSS/nc and α = 0.5 in (4.2). Suppose we take EHSS = na,
i.e., as shown in Figure 4.2, we are willing to borrow nearly all of the adult data’s strength
when p is close to 1 (no significant difference between adult and pediatric PD data).Then
Ψ = 1107/42 = 26.35, and (4.2) gives f(0.05) = 5.9. This indicates a willingness on our part
to base our conclusions on approximately six times as much adult data as pediatric data when the
PK/PD datasets and models suggest no more than borderline statistically significant differences.
At our actual obtained p value from the ”null” and ”full” model PD model comparison in Section
4.2, we have f(0.002) = 1.17. Hence we may seek a power λ that results in an EHSS of roughly
1.17× 42 = 49.5 ≈ 50 adult patients.
Table 4.1 provides our results, all computed using the OpenBUGS language31. We see that
although using the p-value directly as the power (i.e., setting K = 1) does lead to EHSS values
less than na, they are still very large compared to the pediatric data size nc. By contrast,
setting K = 0.1 (i.e., setting λ equal to 1/10 of the observed p-value) does appear to give more
acceptable EHSS values (roughly equal and just a bit larger than nc for our two parameters
of interest, respectively). The table also gives results for the no-borrowing (K = 0) case for
comparison. Of particular substantive interest here is that the overall slope in the drug group,
µpth = η0 + µd, is significantly (i.e., the 95% Bayesian credible interval excludes 0) negative in
the high-borrowing (K = 1) and the more cautious (K = 0.1) cases, but not the no-borrowing
(K = 0) case. Thus if we discard all of the adult data, the efficacy in children is not significant
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η0 µ
pth = η0 + µd
K λ mean sd
BCI
(lower)
BCI
(upper)
EHSS mean sd
BCI
(lower)
BCI
(upper)
EHSS
1 0.002 0.643 0.413 -0.079 1.557 207.198 -1.787 0.380 -2.475 -1.008 246.282
0.1 0.0002 1.015 0.708 -0.335 2.286 42.724 -1.622 0.634 -2.785 -0.285 61.477
0 0 1.254 1.006 -0.678 3.308 0 -1.574 0.995 -3.461 0.459 0
Table 4.1: Posterior estimates for the model coefficients using a power prior for varying values
of λ = Kp. The three rows of the table correspond to K = 1, 0.1, and 0.
statistically. Although K = 0 yielded a negative mean of slope for the drug group (showing
some treatment effect), we arrived at a non-significant result possibly due to the small sample
size of the pediatric study. This further emphasizes our motivation to extrapolate from adult
data because it may have the potential to enable us to arrive at conclusive decisions as seen in
this case.
4.4 Joint Clinical Efficacy and Toxicity Model
In order to jointly accommodate both efficacy and toxicity responses for each patient, we now
specify a mixed effects model to simultaneously describe efficacy (measured by percent change
in iPTH) and toxicity (measured by absolute drop in calcium level, cCa) of the drug among
the adult and pediatric patients. We use the model described in the previous section for the
efficacy measurements Xi,j . For the safety data, we now additionally define Yi,j = cCai,j , the
jth corrected serum calcium observation for the ith patient.
For pediatric patients (i.e., i = 1, ..., nc), we now assume the bivariate normal likelihood[
Xi,j
Yi,j
]
∼ N2(µci,j ,Σ), where µci,j =
[
µc,pthi,j
µc,cCai,j
]
. Similarly we assume for the adults (i = 1, ..., na),[
Xi,j
Yi,j
]
∼ N2(µai,j ,Σ), where µai,j =
[
µa,pthi,j
µa,cCai,j
]
.
The data dispersion matrix is of the form Σ =
[
σ2x ρσxσy
ρσxσy σ2y
]
and we assign priors such
that 1
σ2x
and 1
σ2y
independently follow Gamma(1, 1) distributions, and ρ ∼ Unif(−0.9, 0.9).
Although theoretically the correlation can take values from −1 to 1, for numerical reasons we
bound ρ away from these parameter space endpoints. Fitting a model similar to that in the
univariate case above, we have
µc,pthi,j = η
pth
0 t
c
i,j + I(drug
c
i = 1)µ
pth
d t
c
i,j + ζ
c,pth
i ti,j , i = 1, ..., nc ,
µc,cCai,j = θc + η
cCa
0 t
c
i,j + I(drug
c
i = 1)µ
cCa
d t
c
i,j + ζ
c,cCa
i ti,j , i = 1, ..., nc ,
µa,pthi,j = η
pth
0 t
a
i,j + I(drug
a
i = 1)µ
pth
d t
a
i,j + ζ
a,pth
i ti,j , i = 1, ..., na ,
and µa,cCai,j = θa + η
cCa
0 t
a
i,j + I(drug
a
i = 1)µ
cCa
d t
a
i,j + ζ
a,cCa
i ti,j , i = 1, ..., na . (4.4)
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We then assign
[
ζc,pthi
ζc,cCai
]
∼ t6(0,We) and
[
ζa,pthi
ζa,cCai
]
∼ t6(0,We). In order to choose the degrees
of freedom for our bivariate t priors, we experimented with degrees of freedom 12, 6 and 3. Like
the normal, the t12 prior failed to account for the extreme observations, while both the t3 and
t6 were less affected. In what follows, we use the t6 distribution, to allow ample flexibility to
account for outliers, while limiting the degrees of freedom to ensure model identifiability (and
hence MCMC convergence) is not compromised.
Note that we have introduced intercept terms θc and θa in the pediatric and adult models
for toxicity, respectively. This is because, unlike in the case of iPTH where we are modeling a
percent change from baseline (and hence at time point 0 we expect our percent change to be
zero), in the case of toxicity we are modeling the absolute level of cCa, which is clearly nonzero
at baseline. The random effects scale matrix, We is assigned an inverse Wishart prior with mean
matrix W0 and degrees of freedom w; in our implementation we let W0 = [ 1 00 1 ] and set w = 2,
the smallest value we can choose for this prior to remain proper. We then proceed to assign
priors to parameters related to the cCa model analogous to those assigned for the iPTH model.
Specifically, we assume ηcCa0 , µ
cCa
d , η
pth
0 , and µ
pth
d are assigned vague normal priors with mean
0, and the toxicity intercepts θa and θc are a priori Uniform(0, 20).
We ran this model using the BUGS software (see code in appendix) and the results are given in
Table 4.2. The results displayed for the iPTH (efficacy parameters) are similar to those obtained
in the previous efficacy-only model. As in that model, of interest here is that the overall slope for
efficacy in the drug group is once again more significant when we borrow more from the adults
(K = 1 or K = 0.1 where it is borderline significant) than when we don’t borrow (K = 0). The
overall safety slope is also negative (as we would expect), but not quite significantly so even
for K = 1. The mean posterior estimated ρ for all λ′s investigated lies near −0.15, which is
practically negligible and suggests little correlation between the two endpoints.
We next compute, under λ = 0.0002, the posterior probability of the ith pediatric patient
having a mild toxicity (i.e., cCa value less than 8.4mg/dl) and a severe toxicity (cCa value
less than 7.5mg/dl) at week 24, denoted by ptox24,8.4,i and p
tox
24,7.5,i respectively. Further, we also
calculate a posterior probability of pediatric patients having good efficacy (defined as greater
than 30% reduction in iPTH at week 24), denoted by peff24,30,i, and excellent efficacy (defined
as greater than 50% reduction in iPTH at week 24), denoted by peff24,50,i. Figure 4.3 shows
caterpillar plots corresponding to these four quantities from left to right. The horizontal lines
in the plots are patient-specific 95% BCIs, the dots are patient specific point estimates, and
the vertical lines in each plot denote the mean among that subgroup of patients. The first row
contains the plots for pediatric patients in the drug group, and the second row shows pediatric
patients in the placebo group.
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ηpth0 µ
pth = ηpth0 + µ
pth
d
K λ mean sd
BCI
(lower)
BCI
(upper)
EHSS mean sd
BCI
(lower)
BCI
(upper)
EHSS
1 0.002 0.598 0.350 -0.048 1.399 438.612 -1.455 0.326 -2.082 -0.786 555.894
0.1 0.0002 1.077 0.789 -0.468 2.69 52.87 -1.324 0.715 -2.69 0.010 82.119
0 0 1.664 1.186 -0.594 4.063 0 -0.916 1.23 -3.257 1.592 0
ηcca0 µ
cca = ηcca0 + µ
cca
d
K λ mean sd
BCI
(lower)
BCI
(upper)
EHSS mean sd
BCI
(lower)
BCI
(upper)
EHSS
1 0.002 0.011 0.011 -0.012 0.032 588.796 -0.016 0.011 -0.037 0.006 596.968
0.1 0.0002 0.002 0.001 -0.037 0.041 162.565 -0.017 0.019 -0.054 0.019 170.748
0 0 -0.023 0.045 -0.114 0.063 0 -0.026 0.043 -0.111 0.057 0
Table 4.2: Posterior estimates for the joint model coefficients using a power prior for varying
values of λ.
As can be seen, some patients have no posterior probability of dropping below the toxicity
thresholds of 8.4 or 7.5, while Patient 8 is judged certain to have experienced either mild or
severe toxicity. Specifically, 23 patients have a nonzero probability of mild toxicity, 15 in the
drug group and 8 in the placebo group. From the caterpillar plot we can see that among the
patients in the drug group, patients 8, 13, and 16 all have better-than-even probabilities of severe
toxicity, and therefore should probably discontinue the treatment or seek dose adjustments or
other interventions. Although according to the drug mechanism patients who see a higher
improvement in iPTH are expected to have lower cCa, we don’t see that in every individual
patient, which is agreement with the posterior of ρ.
We do see more patients in the drug group who are more probable to show both moderate
and high efficacy than in the placebo group, as can be seen in the shift in the vertical lines
depicting the means of the groups. The average proportion of good and excellent efficacy is
0.45 and 0.35, respectively in the drug group, and 0.30 and 0.22, respectively in the placebo
group. Thus the mean difference in response probability between the drug and placebo group is
0.15 and 0.13 for good and excellent efficacy, respectively. We do see the mean probabilities of
mild and severe toxicity are also somewhat greater in the drug group than the placebo group:
average mild and severe toxicity is 0.30 and 0.18, respectively in the drug group, and 0.13
and 0.05, respectively in the placebo group. Thus the shifts are 0.17 and 0.13 for mild and
severe toxicity, respectively. Therefore we conclude the drug offers improved efficacy in reducing
iPTH while increasing the risk of toxicity as measured as low cCa which may be subject to a
risk/benefit evaluation.
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4.5 Simulation Study
In this section we will simulate artificial datasets having characteristics based on the available
cinacalcet data to evaluate our procedure’s performance. We begin by simulating a dataset
similar to our cinacalcet trial data data with na = 200 and nc = 10 patients (so na/nc = 20,
similar to the real data), each with observations for every other week from week 1 to 29. The
observations are the iPTH, Xij , and cCa, Yij , and are simulated based on the models used
to describe them in the previous sections with slight modifications for faster computations.
Specifically, and as encouraged by the small ρ estimates in Section 4.4, we assume ρ = 0
and use independent univariate normal random effects distributions. We are able to drop the
t3 random effects distributions of Sections 4.3 and 4.4 since our simulated data should not
feature outlying individuals to the extent that the real data did. As in Section 4.4, we generate[
Xcij
Y cij
]
∼ N2(µcij,Σ), where again µcij =
[
µc,pthij
µc,cCaij
]
and are defined as noted previously but now
for simplicity we assume ζc,pthi ∼ N(0, τpthζ ), ζc,cCai ∼ N(0, τ cCaζ ), and Σ = Diag(σ2X , σ2Y )
(i.e., independence between efficacy and toxicity). Expressions for the adults follow similarly.
We assign true values to the parameters (which help define the effect due to cinacalcet)ηpth,c0 =
0, ηcCa,c0 = 0, η
pth,a
0 = 0, η
cCa,a
0 = 0, θc = 10.5, and θa = 10.5. We also further fix the variances
τpth = σ2X = 66.67, τ
cCa = σ2Y = 0.013, τ
pth
ζ = 0.067, and τ
cCa
ζ = 0.0025, values chosen
to produce simulated data and random effects broadly similar to those in the cinacalcet data.
We can then vary the true values of the µpth,cd , µ
pth,a
d , µ
cCa,c
d and µ
cCa,a
d parameters (which help
define the drug effect) to obtain different scenarios of similarity and dissimilarity between the
adult and pediatric longitudinal trajectories.
In our set up we will begin by assigning equal values of µpth,cd = −1.5 and µpth,ad = −1.5.
This is the case where the adults and pediatric patients are behaving similarly with respect to
the drug efficacy. By contrast we also consider a case where borrowing is not sensible, namely,
µpth,cd = −1.5 but µpth,ad = 0. A similar change could be made to the toxicity slope, either
setting µcCa,cd = µ
cCa,a
d = −0.05 or µcCa,ad = −0.05 but µcCa,cd = −0.3, the latter setting
representing the worrisome case of much higher toxicity in children.
To evaluate our method, as shown in Table 4.3 we calculate the bias in the estimated slope
corresponding to the drug effect. We have simulated data under 4 primary scenarios: when the
adult and pediatric patients behave similarly both in terms of efficacy and toxicity, when the
toxicity is the same but the two groups have different efficacy, when the efficacy in the two groups
is the same but the toxicity is different, and when both the efficacy and toxicity are different
in the two groups. Thus for the iPTH, Biasipth at week 24 is the average of the difference
between the posterior mean and true value, i.e., ((ηˆpth,c0,l + µˆ
pth,c
d,l )×24)− ((ηpth,c0,l +µpth,cd,l )×24),
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averaged over the l = 1, ..., L = 500 fake datasets. Similarly for the toxicity we define BiascCa
as the average difference between the true value and the posterior mean (ηˆcCa,c0,l + µˆ
cCa,c
d,l ) ×
24− (ηcCa,c0,l + µcCa,cd,l )× 24. We also calculate mean squared errors (MSE) at week 24, δiPTH
and δcCa, given for instance by δiPTH = 1LΣ[((ηˆ
pth,c
0,l + µˆ
pth,c
d,l )× 24)− ((ηpth,c0,l +µpth,cd,l )× 24)]2.
Intuitively these MSE and bias values should all be the same for λ = 0, as in that case we do
not borrow anything from the adult dataset and thus their similarity or dissimilarity to the child
data does not play a role. Otherwise we should have larger bias and MSE when the true values
of the adult and child datasets are dissimilar.
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Scenario µcca,ad = −0.05, µcca,cd = −0.05,µpth,ad = −1.5 and µpth,cd = −1.5
1 K λ BiasCCa(SE) MSEcCa(SE) BiasiPTH(SE) MSEiPTH(SE)
0 0 0.02(0.6) 0.36(0.56) 0.05(3.27) 10.67(15.08)
0.1 0.0002 0.01(0.46) 0.21(0.3) -0.03(3.07) 9.42(14.29)
1 0.002 0.02(0.31) 0.1(0.15) 0.16(2.73) 7.46(11.99)
µcca,ad = −0.05, µcca,cd = −0.05, µpth,ad = 0 and µpth,cd = −1.5
2 K λ BiascCa(SE) MSEcCa(SE) BiasiPTH(SE) MSEiPTH(SE)
0 0 -0.01(0.59) 0.35(0.52) -0.1(3.39) 11.47(17.94)
0.1 0.0002 0.01(0.46) 0.21(0.33) 1.35(3.63) 14.98(53.56)
1 0.002 -0.01(0.3) 0.09(0.13) 8.1(4.33) 84.4(82.8)
µcca,ad = −0.05, µcca,cd = −0.3, µpth,ad = −1.5, and µpth,cd = −1.5
3 K λ BiascCa(SE) MSEcCa(SE) BiasiPTH(SE) MSEiPTH(SE)
0 0 0(0.57) 0.33(0.53) -0.04(3.33) 11.04(18)
0.1 0.0002 1.47(0.68) 2.61(2.95) -0.01(3.29) 10.77(18.42)
0.3 0.0006 2.47(0.69) 6.58(3.72) 0.08(3) 8.96(12.84)
1 0.002 3.59(0.57) 13.21(4.18) -0.01(2.73) 7.44(11.39)
µcca,ad = −0.05, µcca,cd = −0.3, µpth,ad = 0, and µpth,cd = −1.5
4 K λ BiascCa(SE) MSEcCa(SE) BiasiPTH(SE) MSEiPTH(SE)
0 0 0.01(0.55) 0.3(0.45) -0.14(3.42) 11.68(18.08)
0.1 0.0002 1.45(0.65) 2.52(2.34) 1.11(3.36) 12.49(23.06)
0.3 0.0006 2.47(0.68) 6.56(3.67) 2.74(3.31) 18.44(27.54)
1 0.002 3.6(0.56) 13.29(4.13) 8.07(4.38) 84.17(89.12)
µcca,ad = −0.05, µcca,cd = −0.3, µpth,ad = −1.5, and µpth,cd = 0
5 K λ BiascCa(SE) MSEcCa(SE) BiasiPTH(SE) MSEiPTH(SE)
0 0 0.01(0.68) 0.47(2.08) -0.23(3.43) 11.77(22.66)
0.1 0.0002 1.41(0.67) 2.42(2.71) -1.25(3.28) 12.27(37.9)
0.3 0.0006 2.5(0.71) 6.74(3.88) -3.03(3.61) 22.15(52.65)
1 0.002 3.57(0.54) 13.01(4.01) -7.97(4.41) 83.04(101.8)
Table 4.3: Results from the simulation study assuming normal random effects.
As seen in Table 4.3, MSEiPTH decreases and BiasiPTH remains roughly 0 as the power
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multiplier K goes up in the case where the two datasets are similar (Scenario 1) because we are
using more of the similar adult data for our pediatric estimation. However when the datasets
are different, we see the bias and MSE for efficacy increasing in K, as we are now using data
based on two different efficacy models. We can also see that the bias and errors for toxicity are
little affected when the true values are different for only for efficacy which is due to our zero
correlation assumption, and vice versa. For instance, the posteriors corresponding to toxicity
are similar for Scenarios 1 and 2 (both good) and for Scenarios 3 and 4 (both bad), since only
efficacy differs across these scenario pairs. Further, the bias and MSE in Scenarios 2, 3 and 4
increases as we borrow more from the discrepant adult data as expected. Incidentally we also
checked a Scenario 5 where the pediatric patients did not benefit from the drug in terms of
efficacy and were more toxic than the adults, and therefore were doing worse in both regards.
The patterns for iPTH are similar to Scenarios 2 and 4 and for cCa were similar to Scenarios 3
and 4, as expected.
As a check on our work, we repeated the simulation reported in Table 4.3 now assuming t3
random effects. To maintain the same random effect variances as in our normal simulation, we
replaced τpthζ and τ
cCa
ζ by 3 times their previous values. Results shown in Table 4.4 show the
same basic patterns.
To summarize our findings, K = 0.1 seems to offer nice improvements in MSE when bor-
rowing is warranted, but limits the bias and keeps MSE from growing too large in the scenarios
where borrowing is not warranted. We recommend investigators perform similar simulations in
their own settings to help choose the crucial adult borrowing parameter K.
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Scenario µcca,ad = −0.05, µcca,cd = −0.05,µpth,ad = −1.5 and µpth,cd = −1.5
1 K λ BiasCCa(SE) MSEcCa(SE) BiasiPTH(SE) MSEiPTH(SE)
0 0 -0.02(0.51) 0.26(0.54) -0.24(2.83) 8.07(13.94)
0.1 0.0002 0.02(0.35) 0.12(0.19) 0.05(2.57) 6.57(11.92)
1 0.002 0(0.21) 0.05(0.06) 0.02(2.3) 5.26(8.45)
µcca,ad = −0.05, µcca,cd = −0.05, µpth,ad = 0 and µpth,cd = −1.5
2 K λ BiascCa(SE) MSEcCa(SE) BiasiPTH(SE) MSEiPTH(SE)
0 0 -0.03(0.52) 0.27(0.63) 0.09(2.68) 7.17(10.04)
0.1 0.0002 -0.01(0.34) 0.12(0.19) 0.92(2.65) 7.85(12.23)
1 0.002 0.01(0.22) 0.05(0.07) 7.23(5.88) 86.71(155.06)
µcca,ad = −0.05, µcca,cd = −0.3, µpth,ad = −1.5, and µpth,cd = −1.5
3 K λ BiascCa(SE) MSEcCa(SE) BiasiPTH(SE) MSEiPTH(SE)
0 0 0.07(1.43) 2.06(41.17) 0.11(2.65) 7.01(12.79)
0.1 0.0002 1.52(0.74) 2.85(3.07) 0.07(2.66) 7.05(11.82)
1 0.002 4.81(0.57) 23.44(5.33) 0.21(2.23) 4.99(8.77)
µcca,ad = −0.05, µcca,cd = −0.3, µpth,ad = 0, and µpth,cd = −1.5
4 K λ BiascCa(SE) MSEcCa(SE) BiasiPTH(SE) MSEiPTH(SE)
0 0 -0.06(0.54) 0.3(1.09) 0.07(2.87) 8.25(18.53)
0.1 0.0002 1.45(0.8) 2.76(3.5) 0.78(2.54) 7.03(10.79)
1 0.002 4.79(0.63) 23.38(5.76) 7.37(5.7) 86.73(147.57)
µcca,ad = −0.05, µcca,cd = −0.3, µpth,ad = −1.5, and µpth,cd = 0
5 K λ BiascCa(SE) MSEcCa(SE) BiasiPTH(SE) MSEiPTH(SE)
0 0 0.05(0.81) 0.66(8.96) 0.01(2.99) 8.92(43.33)
0.1 0.0002 1.51(0.79) 2.9(3.21) -1.02(2.94) 9.64(16.77)
1 0.002 4.73(0.64) 22.81(5.8) -6.99(5.3) 76.84(127.97)
Table 4.4: Results from the simulation study assuming t3 random effects.
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4.6 Piecewise Linear Model for Efficacy
4.6.1 Efficacy-only Model
We next use the data from adult and pediatric clinical studies of Cinacalcet in the context of a
piecewise linear mixed effects Bayesian hierarchical model to study the drug’s effect on iPTH.
From exploratory and other previous empirical and conceptual modeling, a knot, denoted by T0,
for the piecewise model is placed at week t = 14. Thus our longitudinal model for the children
becomes:
Xi,j ∼ Normal(µpthi,j , 1/τe), i = 1, ..., nc
µpthi,j = η0i + µ
c
1ti,j + µ
c
2(ti,j − T0)I(ti,j − T0 > 0)
+ I(drugi = 1)[µ
dc
1 ti,j + µ
dc
2 (ti,j − T0)I(ti,j − T0 > 0)],
where η0i are the subject-level random effects, assumed to independently follow a N(η0, τη)
specification, and η0 is assigned a vague flat prior. We assign a Gamma(0.1, 0.1) prior on τe.
Similarly for the adults, we assume:
Xi,j ∼ Normal(µpthi,j , 1/τe), i = nc + 1, ..., nc + na
µpthi,j = η0i + µ
a
1ti,j + µ
a
2(ti,j − T0)I(ti,j − T0 > 0)
+ I(drugi = 1)[µ
da
1 ti,j + µ
da
2 (ti,j − T0)I(ti,j − T0 > 0)],
where η0i are again iid normal random effects centered around η0, and all µ parameters and η0 are
assigned flat priors. Exploratory analyses suggest our use of a common data precision τe across
both adults and children is reasonable. We assign commensurate priors on the coefficients for the
slopes of the pediatric data in order to help their estimation borrow information from that in the
model fit for adults. Specifically, we assume µc1 ∼ Normal(µa1, 1/τµ), µc2 ∼ Normal(µa2, 1/τµ),
µdc1 ∼ Normal(µda1 , 1/τµd), and µdc2 ∼ Normal(µda2 , 1/τµd). Following Hobbs et al. (2011,
2012) and Section 2.3.2, the precisions τµ and τµd can be usefully assigned not the traditional
gamma, but instead a spike and slab hyperprior. In our case, after a bit of experimentation with
scale we selected:
τµ ∼
{
Normal(20, 0.01) with probability p;
Uniform(0.1, 5)I(0.1, 5) with probability 1− p ,
and τµd ∼
{
Normal(20, 0.01) with probability pd;
Uniform(0.1, 5)I(0.1, 5) with probability 1− pd.
(4.5)
Both these hyperpriors use a ”spike” at 20, and a ”slab” starting near the origin and going up to
5, but we permit different spike probabilities p and pd for the baseline and the drug components.
We take p, pd
iid∼ Bernoulli(q), where we experiment with various choice of q (0.2, 0.5, 0.8).
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Figure 4.4: The piecewise linear model’s regression line for the placebo and cincalcet group, for
an Individual with intercept η0,i equal to zero
We ran this model in OpenBUGS, and the results are as shown in Tables 4.5- 4.6. As seen
in Table 4.5, for both the adult and pediatric group, in the drug group there is a negative slope
until the knot (pediatric CI = (-3.45,-1.98) and adult CI= (-3.31,-3.00)), followed by a slope
insignificantly different from zero after the knot. On the other hand, the placebo group for both
adults and pediatrics have a significantly positive slope until the knot and again a slope near
to 0 after the knot. This indicates that the regression line as shown in Figure 4.4 for the drug
initially drops steeply, and then becomes relatively flat after week 14. On the other hand, the
line corresponding to the placebo group shows an initial increase in iPTH.
Figure 4.5 helps understand the spike and slab priors in (4.5). From these plots it looks like
the prior and the posterior for the placebo group p are very similar, indicating that we are not
learning much about adult vs. child commensurability from the adult population. On the other
hand, the posterior for pd shows that pd is almost always 0 and hence the posterior is a draw
from the Uniform distribution, suggesting little adult-child commensurability in the drug effect.
This is also reflected in the plot for τµd , which is tightly located near 0.
According to our model, the mean posterior predictive probability of a greater than 30%
reduction from baseline in iPTH was 0.049 (sd= 0.21) for placebo but 0.669 (sd 0.47) for
Cinacalcet, indicating that the drug performs much better than placebo on this important
clinical endpoint. Continuing with this theme, Table 4.6 shows the mean posterior probability
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Slope before the knot Slope after the knot
Mean(SD) CI Mean(SD) CI
Adult Placebo 0.805(0.097) (0.65,0.96) 0.04(0.109) (-0.17,0.25)
Drug -3.155(0.093) (-3.31,-3) -0.026(0.102) (-0.22,0.17)
Pediatric Placebo 1.563(0.34) (0.95,2.3) 0.247(0.381) (-0.56,0.96)
Drug -2.712(0.373) (-3.45,-1.98) -0.151(0.542) (-1.26,0.87)
Table 4.5: Posterior Mean Estimates of Slopes of Percent Change in Intact Hormone Over
Time in Piecewise Linear Regression Model (Longitudinal Model) Using Commensurate Priors
to Extrapolate Data from the Adult to the Pediatric Dataset
Figure 4.5: Plots Showing the Prior and Posterior Densities of the Spike and Slab Prior and The
Corresponding p In Them
of true mean difference in percent change in iPTH for Cinacalcet compared with placebo at
monthly time points being greater than pi. The results again indicate very strong performance
by the drug in all but the most extreme case (there is little chance of a 30% improvement in
Week 2).
4.6.2 Joint Efficacy and Toxicity Longitudinal Model: iPTH and cca
To accommodate both efficacy and toxicity responses, we next tried our piecewise linear mixed
effects model for both efficacy (as measured by iPTH) and toxicity (as measured by the excessive
drop in the calcium levels, (cca) among the adult and pediatric patients. We use the model
described above for efficacy measurements Xij and now let Yi,j = ccai,j where, ccai,j denotes
the jth observation on the corrected serum calcium value of the ith patient. Let Zi,j =
[
Xi,j
Yi,j
]
.
Fitting a model similar to that in the iPTH model above, first for the children we have:
51
Week 2 4 6 8 10 12 13
pi
0 1(0.00) 1(0.00) 1(0.00) 1(0.00) 1(0.00) 1(0.00) 1(0.00)
10 0.999(0.02) 0.999(0.01) 1(0.00) 1(0.00) 1(0.00) 1(0.00) 1(0.00)
20 0.996(0.07) 1(0.02) 1(0.02) 1(0.01) 1(0.01) 1(0.01) 1(0.01)
30 0.035(0.185) 0.999(0.038) 0.999(0.025) 1(0.02) 1(0.018) 1(0.013) 1(0.015)
Table 4.6: Posterior Probability of True Mean Difference in Percent Change in Parathyroid
Hormone for Cinacalcet Compared With Placebo at Monthly Time Points (Longitudinal Model)
When Using Commensurate Priors to Extrapolate Information From Adult to Pediatric Data;
Efficacy Safety
Mean SD Mean SD
Placebo 0.04 0.19 0.04 0.20
Cinacalcet 0.68 0.46 0.15 0.4
Table 4.7: Posterior predictive probability of ≥ 30% reduction from baseline in iPTH and
posterior predictive probability of ≤ 8.4% in cCa.
Zi,j ∼ N2(µi,j ,We), i = 1, ..., nc where µi,j =
[
µpthi,j
µccai,j
]
,
µccai,j = η
cca
0i + µ
cca,c
1 ti,j + µ
cca,c
2 (ti,j − T cca0 )I(ti,j − T cca0 > 0)
+ I(drugi = 1)[µ
cca,dc
1 ti,j + µ
cca,dc
2 (ti,j − T cca0 )I(ti,j − T cca0 > 0)],
and µpthij is as given the previous subsection. Similarly for the adults we have Zi,j ∼ N2(µi,j ,We),for
i = nc + 1, ..., nc + na, with the expressions for µ
pth
ij and µ
cca
ij remaining unchanged. The
2X2 matrix We is assigned an Inverse Wishart prior with parameters W0 and w where we
encourage modest shrinkage by setting W0 = [ 1 00 1 ] and w = 20. We then proceed to as-
sign commensurate priors to parameters related to the CCA model analogous to those in the
iPTH model; namely, µcca,c1 ∼ Normal(µcca,a1 , τ ccaµ ), µcca,c2 ∼ Normal(µcca,a2 , τ ccaµ ), µcca,dc1 ∼
Normal(µcca,da1 , τ
cca,d
µ ), and µ
cca,dc
2 ∼ Normal(µcca,da2 , τ cca,dµ ). Finally τµ and τµcca,d are also
assigned the independent spike and slab priors given in (4.5).
We ran this model using the ”Rjags” package in R, and the results are given in Tables 4.7
and 4.8. In Table 4.7, the results displayed related to iPTH are similar to those obtained in
the previous subsection. On the safety side, cca levels below 8.4% are considered mildly toxic,
so the probability of dropping below this (absolute) level is what we hope to control. Our
results suggest a significant efficacy benefit for Cinacalcet (beating placebo 68% to 3%), but a
corresponding slight increase in risk (15% to 4%).
Table 4.8 gives an entire picture of the joint regression model. The patterns found in the
adult data are similar to those in the pediatric data. The slopes for the efficacy part are similar
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Efficacy
Slope before the knot Slope after the knot
Mean(sd) CI Mean(sd) CI
Adult Placebo 0.828(0.086) (0.659,0.997) -0.181(0.11) (-0.398,0.036)
Drug -3.18(0.08) (-0.929,0.293) 0.29 (0.10) (0.093,0.487)
Pediatric Placebo 1.660(0.31) (1.100,2.3) -0.17(0.37) (-0.63,-0.86)
Drug -2.869(0.35) (-3.61, -2.18) 0.016(0.54) (-1.06, 1.03)
Toxicity
Slope before the knot Slope after the knot
Mean(sd) CI Mean(sd) CI
Adult Placebo 0.003(0.001) (0.001,0.005) 0.048(0.019) (0.014,0.086)
Drug -0.088(0.002) (-0.093,-0.084) 0.073(0.019) (0.039,0.11)
Pediatric Placebo 0.002(0.005) (-0.009,0.014) -0.024(0.037) (-0.098, 0.044)
Drug -0.019(0.014) (-0.049,0.009) -0.045(0.035) (-0.114, 0.024)
Table 4.8: Posterior mean estimates of slopes of percent change in iPTH over time and slopes
for cCa levels in the efficacy-toxicity longitudinal model
to that obtained with the standalone efficacy model described in the previous subsection.
4.7 Discussion
In this chapter we have attempted to show how a careful study of PK/PD data can add valuable
input into the controversial question of borrowing from adult data in subsequent pediatric
drug evaluation. Looking at the PD model fit and posterior estimates may well offer a better
understanding of the similarities in the effect of the drug between adults and children, adding
to the justification for adult data borrowing. A quantitative analysis of the goodness of the
PD model fit with or without separating the parameters by adult/peds population (full vs null
models) and the posterior estimates can then sensibly inform the precise degree of adult clinical
data borrowing. Although any “degree of similarity” measure will need to be scaled appropriately,
our data analysis and limited simulation study have shed light on this important selection.
Our approach of using a p-value comparing the ”full” and ”null” PD models as the power in
a second stage efficacy/toxicity model is just one way the PK/PD similarity information could
be utilized. An alternate method to using the PD analysis results could be using the subject-
level random effects ηli in the model and comparing their variance within and between groups.
From NONMEM we can obtain the posterior mean for each individual corresponding to each of
the fixed effect parameters, and carry out an ANOVA to obtain the variance within (Vw) and
variance between (Vb) each age group. We then define a measure Υl = KVwl/(Vwl + Vbl) for
each of the l = 1, .., 5 parameters, where again K is used to scale the result. Small values of Υl
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suggest greater differences between adults and children. As such, the mean or median of these
Υl can then be used as the power in the power prior method of analysis of the longitudinal data.
As yet another alternative, we might judge the similarity of the adult and pediatric results
by directly comparing the posterior distributions of the corresponding adult- and child-specific
main effects in the PD model. For example, we could measure the overlap of the areas under the
two posterior densities. One way to do this would be through the integrated absolute difference,
∆ =
∫ |Pc(θ) − Pa(θ)|dθ, where Pc and Pa denote the posterior distributions for parameter θ
for the children and the adults, respectively. If the densities are entirely separate, the overlap
will be zero and thus ∆ should be 2. By contrast, if two densities are identical, we should
obtain ∆ = 0. Hence, an alternate power to use in our power prior might be K(1 − ∆/2),
where once again K is chosen to calibrate the overall amount of borrowing. Alternatives to
∆ for judging posterior overlap include the Kullback-Liebler divergence,
∫
Pc(θ) log
Pc(θ)
Pa(θ)
dθ, a
discordance measure with many good properties and for which there exist R functions for ready
computation.
The choice of which parameters to consider in order to evaluate the similarity between the
groups remains open to debate. The complexity of the model (and smallness of the pediatric
dataset) also means that our approximate posteriors may be rather unstable. It’s also important
to remember the difference between statistical and practical significance in this setting. Fitted
posteriors may have little to no overlap between the adults and the children, but this may be
due to a very large adult sample size, and not really connote practically meaningful differences
between the groups. In such cases, limited borrowing from adult clinical data may still be
warranted.
The target function f(p) used in Figure 4.2 to map the p-value obtained from the PD
analysis to the EHSS was attractively simple. However, we might also specify a piecewise
function, which increases until a point (say, p=0.05 or 0.20) and then becomes flat, as another
way to incorporate the restriction on maximum allowable EHSS. Also, we used a fat-tailed t
distribution as our prior on the individual-level random effects, to avoid bias in the main effects
due to extremely high iPTH percent change observations. This could also have been taken care
of by modeling the data on the log scale and then fitting a similar model with the usual normal
distributions on the random effects.
We also used simulated data to check that our procedure works as expected for a fixed power
from the PD model. Although our results were consistent with what one would expect, FDA has
historically discouraged borrowing of strength for safety data of any kind. A modification that
can be used to address this issue would be to use differential borrowing, perhaps even taking
K = 0 for toxicity but retaining K > 0 for efficacy. The method as described in the chapter
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is well suited for EMA (EU regulatory) as it does not have similar restrictive opinion and in
fact encourages extrapolation of safety endpoints. Also the joint approach may have broader
application beyond model efficacy and toxicity. For example, it can evaluate co-primary efficacy
endpoints that may or may not be highly correlated. In many disease areas, regulatory agencies
have requested co-primary endpoints to demonstrate both histological improvement (treating
the disease) and symptom improvement (treating the symptom).
As the drug is intuitively expected to cause a larger decrease in percent change of iPTH
from baseline upto a point and then flatten, we also looked into the piecewise model to describe
the efficacy and toxicity of the drug for the longitudinal model. The method to choose the knot
remains an open question.
Chapter 5
Conclusions and Future Work
5.1 Summary Discussion
In Chapter 2, we began by describing binary and continuous longitudinal models used for Phase
III adult and pediatric data. We used a hierarchical Bayesian framework implemented via power
priors and commensurate priors, and showed they were effective ways to combine information
both for of the binary Remicade data and for the longitudinal Cinacalcet data. Future work
looks to larger simulation studies to compare these methods and study their properties. We
will also be using estimated historical sample size as an added statistic to guide the amount
of borrowing for the different methods, especially in the case of Cinacalcet where the current
dataset is very small compared to the historical data.
In Chapter 3, we presented a fully Bayesian method for evaluating the PK and PD of LO,
as well as a Bayesian adaptive design for a Phase IIa trial to determine a dose that shows
improvement in biomarker response and is safe. Advantages of our method include the ability to
get sensible estimates for a PK/PD model using what little data we have, possibly augmented
by expert opinion. Our design is adaptive to interim individual toxicity and efficacy results, a
desirable trait when dealing with a rare pediatric disease like X-ALD. The design also has a
very reasonable Type I error (to guard against the chance that LO is not effective), as well as
reasonably high power to detect the benefit of LO when it is effective, for all values of n that
are feasible for our proposed Phase IIa study.
Limitations of our method here include failure of our preliminary PK/PD data to adequately
inform the posterior estimate of θ2, the parameter corresponding to the endogenous erucic
concentration level. We have also not been able to incorporate individual-level errors in our
model due to its already-high level of complexity. As for the Phase IIa design, our dose-finding
algorithm can be rather sensitive to the precise level of toxicity assumed for LO (Table 3.2),
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and these toxicities are somewhat vaguely defined at present. As such, our model may require
modification if our assumptions are not consistent with real Phase IIa data.
Future work in this area aims to further develop our suite of adaptive clinical trial techniques.
As discussed previously, this design is amenable to various possible models for improvement
in biomarker response. The Emax model will often be preferred based on pharmacological
justification for the drug’s effect on the improvement in biomarker response. An advantage of
using the Emax model in Phase IIa is we can update our model with the new data coming in;
i.e., we can update our estimates of θ4 and θ3 in Phase IIa to make them more reliable. The
subject pool for PK studies is often demographically or medically different from the subject pool
in Phase IIa or Phase III, and hence being able to update the PK/PD parameters at a later
stage may give us an estimate based on a more representative subject sample. Our ultimate
goal is to design a Phase III study using CT/MR-detected brain abnormalities (instead of C26
response) as the primary endpoint.
The novel approach suggested in Chapter 4 was to use another auxiliary dataset, such as
that from an earlier PK-PD analysis, to inform the degree of borrowing. Since the PK-PD
process captures the drug’s mechanism of action in terms of its clearance as well as the dose-
response relationship32, it seems like a sensible metric for estimating the similarity in the way
the drug should affect adults and children. We quantitatively assessed auxiliary data similarity
or dissimilarity, to come up with a more concrete justification for the degree of borrowing in
such problems.
Future work in this area could further fine tune the procedure linking the PD analysis to the
clinical data analysis. For simpler PD models, such as Emax models, we can set up models and
analyze the PD and the clinical data simultaneously in BUGS. This will also allow us to obtain
updated PD parameters to better understand the drug. We can also look at finding systematic
methods to arrive at better scenarios for simulations. There are numerous other combinations
of parameters besides the ones we selected that could have shed additional light on our method.
A novel technique to deal with this could be to use fractional factorial designs to narrow down
to a maximally informative subset of combinations from all possible simulation designs.
5.2 Zellner’s g-prior for Rare and Pediatric Disease
In this section we will suggest the use of Zellner’s g-prior for cautious strength borrowing in rare
and pediatric disease as another possible area for future work. After a brief Subsection 5.2.1
review of the prior, in Subsection 5.2.2 we suggest a modified version to facilitate borrowing of
information from one dataset to another. In Subsection 5.2.3 we propose applying this modified
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Zellner’s prior to simulated datasets to verify that the idea works before applying it to a dataset
in Crohn’s disease, using the modified g-prior in a logit model. Finally, we propose the use of
propensity scores and other methods for choosing g in Subsection 5.2.4.
5.2.1 Review of Zellner’s g-prior
Zellner’s g prior for regression coefficients in a linear model was introduced by Goel and Zellner16.
These authors begin by assuming Y = Xβ +  , a basic regression model. Zellner’s informative
g prior provides an intuitive way of determining how much the prior distribution on β should
contribute to the posterior14,16. Zellner’s prior is
β|σ2, X ∼ Nn(β0, gσ2(XTX)−1)) .
Note that σ2(XTX)−1 is nothing but V ar(βˆ), where βˆ is the usual maximum likelihood estimate
of β. Zellner’s g-prior incorporates the design matrix X in the covariance of the prior, making
it similar to an empirical Bayesian technique to construct a default prior. This leads to a
conditional posterior of the form
β|Y, σ2, X ∼ N
(
1
g + 1
(β0 + gβˆ),
gσ2
g + 1
(XTX)−1)
)
. (5.1)
Zellner’s informative prior produces a simple and intuitive interpretation of the relative weighting
of the prior mean β0 and the MLE βˆ, as well as helping from a computational perspective.
Varying values of g provide different degrees of prior weighting according to (5.1). For instance,
g = 1 implies a prior weight of 50%, g = 10 implies a prior weight of 10%, and g →∞ yields a
diffuse prior.
5.2.2 Modified Zellner’s g-prior
In this subsection we consider a modification to Zellner’s g-prior. Consider two datasets, adult
data D0 and pediatric data D. Let X0 denote the observed covariate values from the adult
dataset, (say, age, the baseline Mayo score, duration of disease, etc.). Let the response variable
in the adult data be Y0, and in the pediatric data be Y . The covariates in the adult data are
in columns of X0 and those in the pediatric data are in the columns of X. Suppose we assume
the model for the adult data is:
Y0 ∼ Nn(X0β0, σ20I) ,
and that we assign vague priors and compute the posterior estimates from the adult data as βˆ0
and σˆ20. Then for the pediatric data, we can now assume the prior for β is
β ∼ N(βˆ0, gσˆ20(XT0 X0)−1) .
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This leads to another closed form posterior for β 30, though slightly more complicated than
(5.1) namely, P (β|Y, σ2) is
N
[(
1
σ2
XTX +
1
gσˆ20
XT0 X0
)−1(
1
σ2
XTY +
1
gσˆ20
XT0 X0βˆ0
)
,
(
1
σ2
XTX +
1
gσˆ20
XT0 X0
)−1]
(5.2)
Thus we have modified Zellner’s method by using a historical dataset. We have utilized
estimates obtained from the historical dataset βˆ and σˆ20 instead of using priors for them, which
not only helps us avoid another set of possible vague priors but also are derived from the historical
dataset, which is often much larger than the current dataset. This modification also uses the
design matrix from a historical dataset instead of the current dataset, as Zellner’s g prior did.
5.2.3 Simulated Datasets
In this subsection we will carry out some simulations to verify that the modified g-prior indeed
works as we wish it to work. We start with an easy case. We simulate an adult dataset with
two covariates each of size 100, and a pediatric dataset of size 50 also with two covariates each.
We will simulate with various values of β0,1, β0,2, β1 and β, all randomly generated numbers
from a Uniform(-10,10). Also, we assume x0,1,i ∼ N(45, sd = 17) and x0,2,i ∼ N(6, sd = 2),
x1,i ∼ N(10, sd = 4) and x2,i ∼ N(1.4, sd = 0.8), random numbers drawn from normal dis-
tributions centered around posterior means and data covariate values from our Remicade data
set. We will study the effect of the prior by varying these parameters and confirming our ability
to estimate the true parameter values. We then will illustrate the approach using our Remicade
dataset.
5.2.4 Choice of g
According to the interpretation of g in the modified Zellner’s g-prior, it is clear that when the
two datasets are different, the choice of g will be crucial. Although g can be chosen based on
expert opinion, we might also use our historical or adult data to help decide what g should be.
This will be particularly helpful in cases when we do not have an expert’s opinion to guide our
choice of g, which is a problem that power prior and other methods also run into.
We propose to explore two methods in the following subsections. First we will consider a
simple method of putting a hyperprior on g. If we have no other information, we can start with
a vague hyperprior, such as an uniform with a large range. The second method we propose is
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the use of a propensity score to estimate how similar the pediatric data are to the adult data,
and then derive our g from that. This method, as we will see, comes with its own limitations
and problems.
Hyperprior on g
Since g controls the amount of borrowing between datasets, its choice is critical. In Bayesian
analysis, a vague prior is often assigned in information-poor settings. In our case, we can assign
g a Uniform(a, b) prior. Since g is always positive, we set a =  > 0 for  = 0.1. Meanwhile,
b should be assigned a large value, which in our simulations was set to 150.
Under this prior, the conditional posterior of g can be derived as follows:
P (g|Y, σ2) ∝ 1
(b− a)g(n2 ) e
− 1
2
[ 1
σ2
Y ′Y+ 1
g
ˆ
σ20
βˆ0
′
X′0X0βˆ0−A′Σ−1A]
∣∣∣∣ 1σ2X ′X + 1gσˆ20X ′0X0
∣∣∣∣− 12 Ia,b(g),
where A = Σ[ 1
σ2
X ′Y + 1
gσˆ20
X ′0X0βˆ0] and Σ = [
1
σ2
X ′X + 1
gσˆ20
βˆ′0X ′0X0βˆ0]−1. This shows that
the posterior of g does involve the data matrices, which indicates the opportunity to learn from
the covariate data. Since this full conditional is not proportional to the prior, Bayesian learning
seems possible, but its extent for any given problem remain unknown.
The results for the analysis of a few simulated datasets can be seen in Tables 5.1 and 5.2.
Table 5.1 contains results from a setting where the two datasets were assumed to be from the
same underlying distributions and models. Let us call this Sample 1. We simulated an adult
dataset with two covariates of size 100 and a pediatric dataset of size 50 also with two covariates.
True values of the parameters were β0,1 = 4.01 and β0,2 = 8.311 as well as the true β1 = 4.01
and β2 = 8.311, all of which are random numbers generated from a Uniform(0, 10) distribution.
Keeping both the underlying distributions the same, we next sampled x0,1,i ∼ N(45, sd = 17),
and x0,2,i ∼ N(6, sd = 2), and for the pediatrics data we sampled x1,i ∼ N(45, sd = 17) and
x2,i ∼ N(6, sd = 2). As mentioned before, we assign a prior Uniform(0.1, 150) prior on g,
as we cannot permit g to be identically 0. As can be seen from the results in Table 5.1, the
posterior mean of g is only slightly smaller than the prior mean, which is approximately 75. This
indicates minimal Bayesian learning about the g from the data.
We now consider a simulated dataset where the two sets are very different, which we call
Sample 2. Again the simulated adult data have two covariates each of size 100, and the pediatric
dataset is of size 50. We set the true β0,1 = 0.461 and β0,2 = −6.296 but the true β1 = 9.11
and β2 = 3.22. We further simulate from x0,1,i ∼ N(45, sd = 17) and x0,2,i ∼ N(6, sd = 2),
and for the pediatric data x1,i ∼ N(45, sd = 17) and x2,i ∼ N(6, sd = 2). We again assign g
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Mean SD CI
β1 4.004 0.012 3.978 4.025
β2 8.353 0.088 8.191 8.546
g 68.159 43.289 1.773 141.449
Table 5.1: The mean, standard deviations and confidence intervals for the model parameters
and g in identical adult and pediatric datasets.
Mean SD CI
β1 0.468 0.0668 0.332 0.429
β2 -6.263 0.504 -7.313 -6.552
g 75.931 43.610 3.705 146.701
Table 5.2: The mean, standard deviations and confidence intervals for the model parameters
and g in not similar adult and pediatric datasets.
the Uniform(0.1, 150) hyperprior. The results can be seen in Table 5.2. The problem with the
estimated g seems to persist. We do expect and get a larger value of g since the datasets are
very different, however the posterior mean and standard deviation for g are still very similar to
that of the prior, which again indicates weak learning from the data.
Thus we may conclude that assigning a vague prior on g doesn’t lead to a significant learning
about g, and hence doesn’t work as a borrowing tool. If we do have some information on g, we
can assign a better informed prior, such as a normal centered around a guess as to its value.
However even in such cases, the results may again not learn much from the data, suggesting we
either fix g or use some other method.
Use of Propensity Scores to Estimate g
Rosenbaum and Rubin 49 proposed the use of propensity scores as a method of adjusting in the
presence of confounding by indication. Traditionally the propensity score is defined as an indi-
vidual’s probability of being treated with the intervention of interest given the complete set of all
information about that individual. The propensity score provides a single metric that summaries
all the information from explanatory variables50. Individual subjects may have the same or sim-
ilar propensity scores, yet some will have received the intervention of interest and others will not.
In our case we redefine our propensity score as the probability that an individual with the
given covariates will belong to the pediatric dataset. This means that if a patient has a higher
propensity score, it is more likely that the patient has the same clinical characteristics as a child.
In our case we will then calculate the scores for each adult patient in our dataset and obtain a
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propensity score for each, using logistic regression in the usual fashion with adult or child status
as the response. We could take the average of all the calculated adult propensity scores p¯ to
get one number for the dataset and use this number to decide if the two datasets are similar, or
to guide data combination (say, by using the average score as a power in a power prior model).
We might also use this propensity score to arrive at our g. The average propensity score
p¯ lies between 0 and 1, and thus we need to convert it to our scale for g, any positive value.
Our proposed approach is to find a function h that maps the propensity score to the g directly.
One possible function to link the average propensity score p¯ to g is h(p¯) = 1p¯ . According
to this function, h(0) → ∞ and h(1) = 1 which is coherent with the properties of g. Note
this approach assumes similarity of the covariate distribution is sufficient to justify borrowing
strength from the adult data; the β coefficients related to the outcome measure may still differ
between the adults and the children. As such the extent of borrowing here is not a function of
the commensurability of the adult and pediatric data.
5.3 Conclusion
In conclusion, in this thesis we have seen some examples and methodologies where we use
hierarchical Bayesian methods to facilitate data extrapolation that help us design and analyze
clinical trials to tackle the limitations of current methods for pediatric trials or trials for rare
disease treatments. The methods described and proposed in this thesis can indeed allow us
to design trials that can be more sensitive toward patients, which is extremely crucial for such
sensitive populations. These methods can also help us tie together various segments of the
clinical trials and therefore base our analysis on more sound reasoning, as shown in Chapter 4.
Therefore we have shown that using Bayesian modeling and specifically the methods proposed
here, we can make data extrapolation a more reliable approach for superior clinical trials that
both drug developers and regulatory are comfortable with and see profit in implementing.
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Appendix A
A.1 BUGS code for Binary response model using Power
Prior for Section 2.2
model{
for(i in 1:2)
{
Y[i]~dbin(p[i],n[i])
p[i]~dbeta((kappa*mu),(kappa*(1-mu)))
s[i]<-alpha0[i]
s2[i]<-(p[i]*alpha0[i])
}
sum1<-sum(s)
sum2<-sum(s2)
kappa<-2
mu<-0.5
thetahat<-sum2/sum1
kappastar<-kappa+sum1
mustar<-((kappa*mu)/kappastar) + (thetahat*sum1/kappastar)
ppb1<-(kappastar*mustar)
ppb2<- (kappastar*(1-mustar))
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Y2~dbin(pp,np)
pp~dbeta(kappastar*mustar,(kappastar*(1-mustar)))
b1<-1
b2<-1
}
A.2 BUGS code for PK/PD Analysis for Section 3.2
## PK/PD WinBUGS code for the X-ALD (Lorenzos Oil) model
## NOTE: In what follows, DV2 = Y in the paper, and DV3 = Z in the paper
model{
for(i in 1:116){
endoerucic[i] theta[2]
emax[i] theta[3]
ec50[i] theta[4]
c26endo[i] theta[5]
eta1[i]dnorm(0,w[1])
eta2[i]dnorm(0,w[2])
eta3[i]dnorm(0,w[3])
eta4[i]dnorm(0,w[4])
eta5[i]dnorm(0,w[5])
eta6[i]dnorm(0,w[6])
for(k in offset[i]: (offset[i+1] ?1)) {
tvclerucic[k] theta[1]*pow((WT[k]/70),0.75)
clerucic[k] tvclerucic[k]
rateerucic[k] DOSE[k] * (35.83)
cssex[k]
rateerucic[k]/clerucic[k]
cssav[k] cssex[k]+endoerucic[i]
precDV2[k] sigma[1]/cssav[k]*cssav[k]
DV2[k]dnorm(cssav[k], precDV2[k])
e[k] emax[i]*cssex[k]
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d[k] ec50[i]+cssex[k]
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effect[k] e[k]/d[k]
diff[k] c26endo[i]-effect[k]
precDV3[k] sigma[2]/(diff[k]*diff[k])
DV3[k]dnorm(diff[k],precDV3[k])
}
}
theta[1]dnorm(42.3,t1)
theta[2]dnorm(0.582,t2)
theta[3]dnorm(0.655,t3)
theta[4]dnorm(3.34,t4)
theta[5]dnorm(0.971,t5)
for (j in 1:6) {w[j] dgamma(1,1)}
for (j in 1:2) {sigma[j] dgamma(0.1,0.1)}
} # end of BUGS code
## INITS:
list(theta = c(42, 0.5, 0.655, 3.34, 0.971),
w = c(1.228, 0.6849, 11.037, 20.61, 0.432, 33.44),
sigma=c(3,43))
## DATA: (NOTE: there are TWO loads, the list here,
and the primary data matrix below)
list(t1=0.04, t2=100, t3=100, t4=0.01, t5=100,
offset=c(
1, 17, 62, 103, 132, 153, 175, 184, 225, 259,
286, 306, 322, 357, 391, 431, 465, 508, 523, 535,
589, 619, 627, 631, 670, 707, 748, 766, 802, 847,
890, 925, 957, 965, 971, 1007, 1032, 1053, 1093,
1119, 1138, 1165, 1203, 1248, 1256, 1277, 1283,
1315, 1356, 1390, 1408, 1436, 1467, 1505,
1543, 1556, 1559, 1604, 1611, 1635, 1650, 1654,
1660, 1689, 1716, 1741, 1766, 1799, 1822, 1847,
1864, 1875, 1893, 1909, 1930, 1951, 1975, 1999,
2002, 2023, 2027, 2053, 2084, 2111, 2124, 2147,
2166, 2182, 2194, 2219, 2248, 2257, 2270, 2285,
2306, 2321, 2330, 2347, 2358, 2371, 2387, 2402,
2409, 2415, 2422, 2433, 2444, 2453, 2468, 2483,
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2497, 2514, 2523, 2530, 2541, 2542, 2550))
## Here is the primary data matrix:
WT[] DOSE[] DV2[] DV3[]
19.5 0.0 0.59 0.46
19.5 9.0 85.19 0.41
19.5 9.0 10.85 0.35
19.5 9.0 5.45 0.45
19.5 9.0 18.47 0.29
19.5 9.0 14.90 0.24
19.5 9.0 16.50 0.40
19.5 9.0 35.75 0.28
22.8 9.4 50.72 0.36
22.8 9.4 11.76 0.30
22.8 9.4 9.17 0.43
22.8 9.4 71.82 0.51
25.4 9.8 2.05 0.58
. . .. . ..[snip]. . .. . ..
35.2 10.8 24.77 0.45
END
A.3 BUGS Code for Joint Clinical Efficacy and Toxicity
Model
for Section 4.4
Here is the BUGS code used to fit the joint power prior linear model for the Cincalcet data:
model
{
C <-100000
#individual random errors (assume only random slopes)
for (i in 1:Ntot)
{
mueta[i,1] <- eta0 + kdrug[i]*mud
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mueta[i,2] <- eta0tox + kdrug[i]*mudtox
eta0_subj[i,1:2] ~ dmt(mueta[i,], tau_eta0[,],6)
}
const <- -0.5/(1-pow(rho,2))
##Pediatric
for (i in 1:N1)
{
for (j in 1:Tmax[i])
{
muY[i,j] <- eta0_subj[i,1]*t[i,j]
muYtox[i,j] <- thetaC + eta0_subj[i,2]*t[i,j]
logL[i,j] <- 0.5 * log(tau.e*tau.etox) - 0.5*log(1-pow(rho,2))
+const*(Y[i,j]-muY[i,j])*(Y[i,j]-muY[i,j])*tau.e
- const*2*rho*(Y[i,j]-muY[i,j])*(Ytox[i,j]-muYtox[i,j])
*pow((tau.e*tau.etox),0.5)
+ const*(Ytox[i,j]-muYtox[i,j])*(Ytox[i,j]-muYtox[i,j])*tau.etox
}
muYtox24[i] <- thetaC + eta0_subj[i,2]*24
muY24[i] <- eta0_subj[i,1]*24
ptox24[i]<-step(8.4-muYtox24[i])
ptox2475[i]<-step(7.5-muYtox24[i])
peff24[i]<-1-step(30+muY24[i])
peff2420[i]<-1-step(20+muY24[i])
peff2450[i]<-1-step(50+muY24[i])
l[i] <- alphaC*sum(logL[i,1:Tmax[i]])
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phi[i]<- - l[i]+C
zero[i]~dpois(phi[i]); useless[i] <- zerotox[i]
}
###Adults
for (i in (N1+1):Ntot)
{
for (j in 1:Tmax[i])
{
muY[i,j] <- eta0_subj[i,1]*t[i,j]
muYtox[i,j] <- thetaA + eta0_subj[i,2]*t[i,j]
logL[i,j] <- 0.5 * log(tau.e*tau.etox) - 0.5*log(1-pow(rho,2))
+const*(Y[i,j]-muY[i,j])*(Y[i,j]-muY[i,j])*tau.e
- const*2*rho*(Y[i,j]-muY[i,j])*(Ytox[i,j]-muYtox[i,j])
*pow((tau.e*tau.etox),0.5)
+ const*(Ytox[i,j]-muYtox[i,j])*(Ytox[i,j]-muYtox[i,j])*tau.etox
}
l[i] <- alphaA*sum(logL[i,1:Tmax[i]])
phi[i]<- - l[i]+C
zero[i]~dpois(phi[i]); useless[i] <- zerotox[i]
}
#Priors
eta0 ~ dnorm(0,0.01)
eta0tox ~ dnorm(0,0.01)
Omega[1,1] <- 1
Omega[2,2] <- 1
Omega[1,2] <- 0
Omega[2,1] <- 0
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tau_eta0[1:2, 1:2]~ dwish(Omega[,], 2)
tau.e~dgamma(1,1)
tau.etox~ dgamma(1,1)
rho~dunif(-0.9,0.9)
thetaC~dunif(0,20)
thetaA~dunif(0,20)
mud ~ dnorm(0,0.01)
mudtox ~ dnorm(0,0.01)
drugslope <- mud + eta0
drugslopetox <- mudtox + eta0tox
}
